var docs;if (!docs) docs =[]; docs["118"]={"11800":"<p><b>Title</b> Diclofenac (Systemic) / CYP2C9 Inducers (Moderate)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP2C9 Inducers (Moderate) may decrease the serum concentration of Diclofenac (Systemic). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for possible decreased therapeutics effects of diclofenac in patients receiving moderate CYP2C9 inducers.</p>\n<div>\n <p><b>CYP2C9 Inducers (Moderate) Interacting Members</b> Enzalutamide, RifAMPin</p>\n</div> \n<p><b>Discussion</b> Diclofenac prescribing information warns that coadministration with CYP2C9 inducers may decrease diclofenac exposure and efficacy.<sup>1</sup><br><br>The impact of CYP2C9 induction on diclofenac disposition is not well characterized. A study in rhesus monkeys showed no change in diclofenac clearance with rifampin.<sup>2</sup> In contrast, in vitro investigations have consistently predicted a central role of CYP2C9 in diclofenac metabolism in vivo, primarily via its role in catalyzing formation of the most abundant, 4-hydroxy, metabolite.<sup>1,3,4</sup> Several other enzymes may make smaller contributions to total diclofenac metabolism, including UGT2B7 and CYPs 3A4, 2C8, 2C18, 2C19, and 2B6.<sup>1,3,4,5,6</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Voltaren XR (diclofenac sodium extended-release). East Hanover, NJ: Novartis Pharmaceuticals Corporation, February 2011.</p>\n<p>2. Prueksaritanont T, Li C, Tang C, et al, “Rifampin Induces the In Vitro Oxidative Metabolism, but Not the In Vivo Clearance of Diclofenac in Rhesus Monkeys,” <i>Drug Metab Dispos</i>, 2006, 34(11):1806-10. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16928785\">[PubMed 16928785]</a></p>\n<p>3. Bort R, Mace K, Boobis A, et al, “Hepatic Metabolism of Diclofenac: Role of Human CYP in the Minor Oxidative Pathways,” <i>Biochem Pharmacol</i>, 1999, 58: 787-96. [PMID 10449188]</p>\n<p>4. Tang W, Stearns RA, Wang RW, et al, “Roles of Human Hepatic Cytochrome P450s 2C9 and 3A4 in the Metabolic Activation of Diclofenac,” <i>Chem Res Toxicol</i>, 1999, 12(2):192-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10027798\">[PubMed 10027798]</a></p>\n<p>5. Shen S, Marchick MR, Davis MR, et al, “Metabolic Activation of Diclofenac by Human Cytochrome P450 3A4: Role of 5-Hydroxydiclofenac,” <i>Chem Res Toxicol</i>, 1999, 12(2):214-22. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10027801\">[PubMed 10027801]</a></p>\n<p>6. Kumar S, Samuel K, Subramanian R, et al, “Extrapolation of Diclofenac Clearance From In Vitro Microsomal Metabolism Data: Role of Acyl Glucuronidation and Sequential Oxidative Metabolism of the Acyl Glucuronide,” <i>J Pharmacol Exp Ther</i>, 2002, 303(3):969-78. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12438516\">[PubMed 12438516]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11801":"<p><b>Title</b> CYP2C9 Substrates (High risk with Inducers) / CYP2C9 Inducers (Moderate)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP2C9 Inducers (Moderate) may decrease the serum concentration of CYP2C9 Substrates (High risk with Inducers). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for decreased effects of the CYP substrates listed in this monograph if a CYP inducer is initiated/dose increased, and for increased effects if a CYP inducer is discontinued/dose decreased (note that the opposite effects are expected for some inactive prodrugs).</p>\n<div>\n <p><b>CYP2C9 Inducers (Moderate) Interacting Members</b> Enzalutamide, RifAMPin</p>\n <p><b>CYP2C9 Substrates (High risk with Inducers) Interacting Members</b> Acenocoumarol, Benzbromarone, Celecoxib, ChlorproPAMIDE, Dapsone (Systemic), Etravirine, FLUoxetine, Fosphenytoin, Gliclazide, Glimepiride, GlipiZIDE, GlyBURIDE, Ketamine, Lesinurad, Losartan, Meloxicam, Mestranol, Nateglinide, Ospemifene, Phenytoin, Piroxicam (Systemic), SulfADIAZINE, Sulfamethoxazole, Sulfinpyrazone, SulfiSOXAZOLE, Tamoxifen, TOLBUTamide, Torsemide, Trimethoprim, Voriconazole, Warfarin, Zafirlukast</p>\n</div> \n<p><b>Discussion</b> The CYP inducers listed in this monograph will probably increase the metabolism of the substrates of this pathway. Substrate clearance would increase and serum concentrations would decrease. Decreased effects of the substrates are expected (note that the opposite effect is expected for some inactive prodrugs).<br><br>CYP substrates are included in this monograph because a) the identified cytochrome P450 pathway is responsible for at least 30% of the metabolism of the substrate; and b) a significant decrease in serum concentration of the substrate (ie, more than 50%) could result in clinically relevant pharmacodynamic effects.<br><br>CYP inducers have been labeled “moderate” because they have been shown to cause significant increases in CYP activity, and, as a result, significant increases in the clearance of drugs metabolized by this pathway.<sup>1,2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Bjornsson TD, Callaghan JT, Einolf HJ, et al; Pharmaceutical Research and Manufacturers of America Drug Metabolism/Clinical Pharmacology Technical Working Groups. The conduct of in vitro and in vivo drug-drug interaction studies: a PhRMA perspective. <i>J Clin Pharmacol</i>. 2003;43(5):443-469. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12751267\">[PubMed 12751267]</a></p>\n<p>2. US Department of Health and Human Services. Food and Drug Administration. Center for Drug Evaluation and Research (CDER). Guidance for Industry: Drug Interaction Studies -- Study Design, Data Analysis, Implications for Dosing, and Labeling Recommendations. http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm292362.pdf. Published February 2012. Accessed March 18, 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11802":"<p><b>Title</b> CYP2C9 Substrates (High risk with Inducers) / Rifapentine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Rifapentine may decrease the serum concentration of CYP2C9 Substrates (High risk with Inducers). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for decreased effects of CYP2C9 substrates (or increased effects if CYP2C9 is required for activation of a prodrug) when combined with rifapentine.</p>\n<div>\n <p><b>CYP2C9 Substrates (High risk with Inducers) Interacting Members</b> Acenocoumarol, Benzbromarone, Celecoxib, ChlorproPAMIDE, Dapsone (Systemic), Etravirine, FLUoxetine, Fosphenytoin, Gliclazide, Glimepiride, GlipiZIDE, GlyBURIDE, Ketamine, Lesinurad, Losartan, Meloxicam, Mestranol, Nateglinide, Ospemifene, Phenytoin, Piroxicam (Systemic), SulfADIAZINE, Sulfamethoxazole, Sulfinpyrazone, SulfiSOXAZOLE, Tamoxifen, TOLBUTamide, Torsemide, Trimethoprim, Voriconazole, Warfarin, Zafirlukast</p>\n</div> \n<p><b>Discussion</b> Rifapentine prescribing information states that rifapentine is an inducer of CYP2C9.<sup>1</sup> Although rifapentine has been shown to induce CYP2C9 in vitro, no clinical studies have evaluated the effect of rifapentine on the exposure to CYP2C9 substrates (eg, warfarin, phenytoin).<sup>2</sup> However, because rifapentine is structurally related to rifampin, a known CYP2C9 inducer, prescribing information warns that rifapentine may reduce concentrations and effects of CYP2C9 substrates.<sup>1</sup> Patients should be monitored closely and dose adjustments of the CYP2C9 substrate may be required.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Priftin (rifapentine) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis US LLC; November 2014. </p>\n<p>2. Li AP, Reith MK, Rasmussen A, et al. Primary human hepatocytes as a tool for the evaluation of structure-activity relationship in cytochrome P450 induction potential of xenobiotics: evaluation of rifampin, rifapentine, and rifabutin. <i>Chem Biol Interact</i>. 1997;107(1-2):17-30. [PubMed 9402947]</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11803":"<p><b>Title</b> Alcohol (Ethyl) / Niclosamide</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Niclosamide may increase the absorption of Alcohol (Ethyl). <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid the concomitant use of niclosamide and alcohol-containing beverages.</p> \n<p><b>Discussion</b> The product labeling for niclosamide advises to avoid the concomitant use of niclosamide and alcohol-containing beverages. There are no additional data or recommendations provided. The mechanism for this possible interaction is unknown; however, niclosamide use may increase alcohol absorption from the gastrointestinal tract.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Nicloside tablets [summary of product characteristics]. Alexandria, Egypt: Alexandria Company for Pharmaceuticals and Chemical Industries; March 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11804":"<p><b>Title</b> Sulfonamide Antibiotics / Pyrimethamine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Pyrimethamine may enhance the adverse/toxic effect of Sulfonamide Antibiotics. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for increased hematologic toxicities and folate deficiency if pyrimethamine is combined with sulfonamide antibiotics. If signs of folate deficiency develop, pyrimethamine should be discontinued. Folinic acid (leucovorin) should be administered until normal hematopoiesis is restored. The combination product pyrimethamine and sulfadoxide should not be combined with other sulfonamide antibiotics.</p>\n<div>\n <p><b>Sulfonamide Antibiotics Interacting Members</b> SulfADIAZINE, Sulfadoxine, Sulfamethoxazole, SulfiSOXAZOLE</p>\n</div> \n<p><b>Discussion</b> The pyrimethamine prescribing information states that the concomitant use of other antifolic drugs or agents associated with myelosuppression including sulfonamide antibiotics, trimethoprim-sulfamethoxazole combinations, proguanil, or cytostatic agents (eg, methotrexate), while the patient is receiving pyrimethamine, may increase the risk of bone marrow suppression.<sup>1</sup> If signs of folate deficiency develop, pyrimethamine should be discontinued. Folinic acid (leucovorin) should be administered until normal hematopoiesis is restored.<sup>1</sup> The combination product pyrimethamine and sulfadoxide should not be combined with other sulfonamide antibiotics.<sup>2</sup><br><br>The mechanism of this interaction is likely due to additive effects on folic acid suppression by pyrimethamine and other antifolic drugs.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Daraprim (pyrimethamine) [prescribing information]. New York, NY: Turing Pharmaceuticals LLC; June 2017.</p>\n<p>2. Fandisar (pyrimethamine and sulfadoxine) [summary of product characteristics]. New South Wales, Australia: Roche Products Pty Limited; April, 2008.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11805":"<p><b>Title</b> Trimethoprim / Pyrimethamine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Pyrimethamine may enhance the adverse/toxic effect of Trimethoprim. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for increased hematologic toxicities and folate deficiency if pyrimethamine is combined with trimethoprim. If signs of folate deficiency develop, pyrimethamine should be discontinued. Folinic acid (leucovorin) should be administered until normal hematopoiesis is restored. Trimethoprim and pyrimethamine may potentiate cutaneous reactions which may require discontinuation or modification in therapy.</p> \n<p><b>Discussion</b> The pyrimethamine prescribing information states that the concomitant use of other antifolic drugs or agents associated with myelosuppression including sulfonamide antibiotics, trimethoprim-sulfamethoxazole (CTX) combinations, proguanil, or cytostatic agents (eg, methotrexate), while the patient is receiving pyrimethamine, may increase the risk of bone marrow suppression.<sup>1</sup> If signs of folate deficiency develop, pyrimethamine should be discontinued. Folinic acid (leucovorin) should be administered until normal hematopoiesis is restored.<sup>1</sup><br><br>In a case surveillance study of 17 government health clinics, rates of Steven Johnson Syndrome (SJS) and toxic epidermal necrosis (TEN) were higher with the combination sulfadoxine-pyrimethamine (SP) and CTX (3.4 cases per 100,000 exposures) versus SP or CTX alone (1.2 and 1.5 cases out of 100,000 exposures).<sup>2</sup> Rates of adverse effects were cutaneous reactions defined as 2 out 3 of the following symptoms: 1) a wide-spread, disseminated rash, 2) blisters or skin detachment &gt; 3 cm in diameter, or 3) lesions on at least one mucous membrane.<sup>2</sup><br><br>The mechanism of this myelosuppression interaction is likely due to additive effects on folic acid suppression by pyrimethamine and other antifolic drugs. Reasons for increased incidence of severe cutaneous rashes, SJS and TEN, with this combination are unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Daraprim (pyrimethamine) [prescribing information]. New York, NY: Turing Pharmaceuticals LLC; June 2017.</p>\n<p>2. Gimnig JE, MacArthur JR, M'Bang'ombe M, et al. Severe cutaneous reactions to sulfadoxine-pyramethamine and trimethoprim-sulfamethoxazole in Blantyre District, Malawi. <i>Am J Trop Med Hyg</i> 2006;74(5):738-743. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16687672\">[PubMed 16687672]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11806":"<p><b>Title</b> Proguanil / Pyrimethamine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Pyrimethamine may enhance the adverse/toxic effect of Proguanil. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for increased hematologic toxicities and folate deficiency if pyrimethamine is combined with proguanil. If signs of folate deficiency develop, pyrimethamine should be discontinued. Folinic acid (leucovorin) should be administered until normal hematopoiesis is restored.</p> \n<p><b>Discussion</b> The pyrimethamine prescribing information states that the concomitant use of other antifolic drugs or agents associated with myelosuppression including sulfonamide antibiotics, trimethoprim-sulfamethoxazole combinations, proguanil, or cytostatic agents (eg, methotrexate), while the patient is receiving pyrimethamine, may increase the risk of bone marrow suppression.<sup>1</sup> If signs of folate deficiency develop, pyrimethamine should be discontinued. Folinic acid (leucovorin) should be administered until normal hematopoiesis is restored.<sup>1</sup><br><br>The mechanism of this interaction is likely due to additive effects on folic acid suppression by pyrimethamine and other antifolic drugs.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Daraprim (pyrimethamine) [prescribing information]. New York, NY: Turing Pharmaceuticals LLC; June 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11807":"<p><b>Title</b> Methotrexate / Pyrimethamine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Pyrimethamine may enhance the adverse/toxic effect of Methotrexate. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for increased hematologic toxicities and folate deficiency if pyrimethamine is combined with methotrexate. If signs of folate deficiency develop, pyrimethamine should be discontinued. Folinic acid (leucovorin) should be administered until normal hematopoiesis is restored.</p> \n<p><b>Discussion</b> The pyrimethamine prescribing information states that the concomitant use of other antifolic drugs or agents associated with myelosuppression including sulfonamide antibiotics, trimethoprim-sulfamethoxazole combinations, proguanil, or cytostatic agents (eg, methotrexate), while the patient is receiving pyrimethamine, may increase the risk of bone marrow suppression.<sup>1</sup> If signs of folate deficiency develop, pyrimethamine should be discontinued. Folinic acid (leucovorin) should be administered until normal hematopoiesis is restored.<sup>1</sup><br><br>The mechanism of this interaction is likely due to additive effects on folic acid suppression by pyrimethamine and other antifolic drugs.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Daraprim (pyrimethamine) [prescribing information]. New York, NY: Turing Pharmaceuticals LLC; June 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11808":"<p><b>Title</b> PEMEtrexed / Pyrimethamine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Pyrimethamine may enhance the adverse/toxic effect of PEMEtrexed. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for increased hematologic toxicities and folate deficiency if pyrimethamine is combined with pemetrexed. If signs of folate deficiency develop, pyrimethamine should be discontinued. Folinic acid (leucovorin) should be administered until normal hematopoiesis is restored.</p> \n<p><b>Discussion</b> The pyrimethamine prescribing information states that the concomitant use of other antifolic drugs or agents associated with myelosuppression including sulfonamide antibiotics, trimethoprim-sulfamethoxazole combinations, proguanil, or cytostatic agents (eg, methotrexate), while the patient is receiving pyrimethamine, may increase the risk of bone marrow suppression.<sup>1</sup> If signs of folate deficiency develop, pyrimethamine should be discontinued. Folinic acid (leucovorin) should be administered until normal hematopoiesis is restored.<sup>1</sup><br><br>The mechanism of this interaction is likely due to additive effects on folic acid suppression by pyrimethamine and other antifolic drugs.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Daraprim (pyrimethamine) [prescribing information]. New York, NY: Turing Pharmaceuticals LLC; June 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11809":"<p><b>Title</b> PRALAtrexate / Pyrimethamine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Pyrimethamine may enhance the adverse/toxic effect of PRALAtrexate. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for increased hematologic toxicities and folate deficiency if pyrimethamine is combined with pralatrexate. If signs of folate deficiency develop, pyrimethamine should be discontinued. Folinic acid (leucovorin) should be administered until normal hematopoiesis is restored.</p> \n<p><b>Discussion</b> The pyrimethamine prescribing information states that the concomitant use of other antifolic drugs or agents associated with myelosuppression including sulfonamide antibiotics, trimethoprim-sulfamethoxazole combinations, proguanil, or cytostatic agents (eg, methotrexate), while the patient is receiving pyrimethamine, may increase the risk of bone marrow suppression.<sup>1</sup> If signs of folate deficiency develop, pyrimethamine should be discontinued. Folinic acid (leucovorin) should be administered until normal hematopoiesis is restored.<sup>1</sup><br><br>The mechanism of this interaction is likely due to additive effects on folic acid suppression by pyrimethamine and other antifolic drugs.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Daraprim (pyrimethamine) [prescribing information]. New York, NY: Turing Pharmaceuticals LLC; June 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11810":"<p><b>Title</b> Raltitrexed / Pyrimethamine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Pyrimethamine may enhance the adverse/toxic effect of Raltitrexed. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for increased hematologic toxicities and folate deficiency if pyrimethamine is combined with ralitrexed. If signs of folate deficiency develop, pyrimethamine should be discontinued. Folinic acid (leucovorin) should be administered until normal hematopoiesis is restored.</p> \n<p><b>Discussion</b> The pyrimethamine prescribing information states that the concomitant use of other antifolic drugs or agents associated with myelosuppression including sulfonamide antibiotics, trimethoprim-sulfamethoxazole combinations, proguanil, or cytostatic agents (eg, methotrexate), while the patient is receiving pyrimethamine, may increase the risk of bone marrow suppression.<sup>1</sup> If signs of folate deficiency develop, pyrimethamine should be discontinued. Folinic acid (leucovorin) should be administered until normal hematopoiesis is restored.<sup>1</sup><br><br>The mechanism of this interaction is likely due to additive effects on folic acid suppression by pyrimethamine and other antifolic drugs.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Daraprim (pyrimethamine) [prescribing information]. New York, NY: Turing Pharmaceuticals LLC; June 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11811":"<p><b>Title</b> OXcarbazepine / CYP3A4 Inducers (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP3A4 Inducers (Strong) may decrease the serum concentration of OXcarbazepine. Specifically, the concentrations of the 10-monohydroxy active metabolite of oxcarbazepine may be decreased. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor patients for decreased concentrations of the 10-monohydroxy active metabolite of oxcarbazepine if combined with strong CYP3A4 inducers. Dose adjustment of oxcarbazepine may be required.</p>\n<div>\n <p><b>CYP3A4 Inducers (Strong) Interacting Members</b> Apalutamide, CarBAMazepine, Enzalutamide, Fosphenytoin, Lumacaftor, Mitotane, PHENobarbital, Phenytoin, Primidone, RifAMPin</p>\n</div> \n<p><b>Discussion</b> In several pharmacokinetic studies described in the oxcarbazepine prescribing information, concomitant use of oxcarbazepine with various strong CYP3A4/uridine diphosphate glycosyltransferase (UGT) inducers decreased serum concentrations of the 10-monohydroxy (MHD) active metabolite.<sup>1</sup> Phenytoin, carbamazepine, and phenobarbital deceased MHD concentrations 30%, 40%, and 25%, respectively.<sup>1</sup><br><br>Oxcarbazepine prescribing information states that if oxcarbazepine is combined with strong CYP3A4 inducers or UGT inducers, then MHD concentrations should be monitored closely.<sup>1</sup> Oxcarbazepine dose adjustments may be required after initiation, dosage modification, or discontinuation of such inducers.<sup>1</sup><br><br>The mechanism of this interaction is likely due to induction of UGTs and/or CYP3A4. The MHD metabolite is eliminated primarily through glucuronidation, with oxidative pathways (ie, CYP3A4) playing only a minor role in its elimination.<sup>1</sup> Because many CYP3A4 inducers also induce UGTs, prescribing information warns that caution and additional monitoring of MHD concentrations is warranted when oxcarbazepine is combined with strong CYP3A4 inducers.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Trileptal (oxcarbazepine) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corp; November 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11822":"<p><b>Title</b> Angiotensin II / Angiotensin-Converting Enzyme Inhibitors</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Angiotensin-Converting Enzyme Inhibitors may enhance the therapeutic effect of Angiotensin II. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased angiotensin II effects/toxicities if given to patients taking angiotensin-converting enzyme (ACE) inhibitors. While ACE inhibitors and other antihypertensive agents should be discontinued in patients being treated for septic or distributive shock, clinicians should be aware that recent ACE inhibitor use may enhance the effects of angiotensin II therapy.</p>\n<div>\n <p><b>Angiotensin-Converting Enzyme Inhibitors Interacting Members</b> Alacepril, Benazepril, Captopril, Cilazapril, Enalapril, Enalaprilat, Fosinopril, Imidapril, Lisinopril, Moexipril, Perindopril, Quinapril, Ramipril, Trandolapril, Zofenopril</p>\n</div> \n<p><b>Discussion</b> Prescribing information for angiotensin II states that concomitant use of angiotensin-converting enzyme (ACE) inhibitors may increase the response to angiotensin II therapy.<sup>1</sup> The mechanism of this interaction may be due the ACE enzyme being at least partially responsible for angiotensin II metabolism.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Giapreze (angiotensin II) [prescribing information]. San Diego, CA: La Jolla Pharmaceutical Company; December 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11823":"<p><b>Title</b> Angiotensin II / Angiotensin II Receptor Blockers</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Angiotensin II Receptor Blockers may diminish the therapeutic effect of Angiotensin II. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for decreased angiotensin II efficacy if given to patients taking angiotensin II receptor blockers (ARBs). While ARBs and other antihypertensive agents should be discontinued in patients being treated for septic or distributive shock, clinicians should be aware that recent ARB use may reduce the efficacy of angiotensin II therapy.</p>\n<div>\n <p><b>Angiotensin II Receptor Blockers Interacting Members</b> Azilsartan, Candesartan, Eprosartan, Fimasartan, Irbesartan, Losartan, Olmesartan, Telmisartan, Valsartan</p>\n</div> \n<p><b>Discussion</b> Because angiotensin II receptor blockers (ARBs) antagonize the angiotensin II receptor, concomitant use will likely block the effects of angiotensin II and impair its efficacy.<sup>1</sup> Complete elimination of the ARB (up to 5 half-lives) may be required to restore angiotensin II efficacy.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Giapreze (angiotensin II) [prescribing information]. San Diego, CA: La Jolla Pharmaceutical Company; December 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11824":"<p><b>Title</b> Ertugliflozin / RifAMPin</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> RifAMPin may decrease the serum concentration of Ertugliflozin. <b>Severity</b> Minor <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> In a pharmacokinetic study described in the ertugliflozin prescribing information, rifampin (600 mg daily) decreased the ertugliflozin (15 mg single dose) AUC and maximum serum concentration 39% and 15%, respectively.<sup>1</sup> These changes in exposure are not considered clinically relevant.<sup>1</sup><br><br>The mechanism of this interaction is likely due to rifampin-mediated induction of the UGTs responsible for ertugliflozin metabolism.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Steglatro (ertugliflozin) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co Inc; December 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11825":"<p><b>Title</b> Ertugliflozin / Mefenamic Acid</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Mefenamic Acid may increase the serum concentration of Ertugliflozin. <b>Severity</b> Minor <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> The ertugliflozin prescribing information states that pharmacokinetic modeling studies suggest that coadministration of mefenamic acid with ertugliflozin may increase the ertugliflozin AUC and maximum serum concentration 51% and 19%, respectively.<sup>1</sup> These predicted changes in exposure are not considered clinically relevant.<sup>1</sup><br><br>The mechanism of this potential interaction is likely mefenamic acid-mediated inhibition of the UGTs responsible for ertugliflozin metabolism.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Steglatro (ertugliflozin) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co Inc; December 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11826":"<p><b>Title</b> Macimorelin / CYP3A4 Inducers (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> CYP3A4 Inducers (Strong) may decrease the serum concentration of Macimorelin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Discontinue strong CYP3A4 inducers prior to macimorelin use. A sufficient washout period should be provided after discontinuation of strong CYP3A4 inducers prior to macimorelin administration. Concomitant use may lead to false-positive test results.</p>\n<div>\n <p><b>CYP3A4 Inducers (Strong) Interacting Members</b> Apalutamide, CarBAMazepine, Enzalutamide, Fosphenytoin, Lumacaftor, Mitotane, PHENobarbital, Phenytoin, Primidone, RifAMPin</p>\n</div> \n<p><b>Discussion</b> The macimorelin prescribing information states that because macimorelin is metabolized by CYP3A4, use of strong CYP3A4 inducers may reduce the plasma macimorelin concentrations and may lead to false-positive test results.<sup>1</sup> Strong CYP3A4 inducers should be discontinued prior to macimorelin use and a sufficient washout period should be provided after discontinuation of strong CYP3A4 inducers prior to macimorelin administration.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Macrelin (macimorelin) [prescribing information]. Frankfurt am Main, Germany; Aeterna Zentaris GmbH: December 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11827":"<p><b>Title</b> QTc-Prolonging Agents (Highest Risk) / Macimorelin</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Macimorelin may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk). <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Avoid concomitant use of macimorelin and drugs that prolong the QT interval. A sufficient washout period should be provided after discontinuation of drugs that prolong the QT interval prior to macimorelin administration.</p>\n<div>\n <p><b>QTc-Prolonging Agents (Highest Risk) Interacting Members</b> Ajmaline, Amiodarone, Anagrelide, Arsenic Trioxide, Artemether, Asenapine, Astemizole, Bepridil, Cisapride, Citalopram, Deutetrabenazine, Disopyramide, Dofetilide, Domperidone, Dosulepin, Dronedarone, Eliglustat, FLUoxetine, Flupentixol, Halofantrine, Ibutilide, Iloperidone, Lopinavir, Lumefantrine, MiFEPRIStone, Nilotinib, Paliperidone, Pimavanserin, Pimozide, Pipamperone [INT], Procainamide, QUEtiapine, QuiNIDine, QuiNINE, Radotinib, Ribociclib, Sotalol, Sparfloxacin, Sulpiride, Terfenadine, Tetrabenazine, Thioridazine, Toremifene, Vandetanib, Vemurafenib, Vernakalant, Ziprasidone, Zuclopenthixol</p>\n</div> \n<p><b>Discussion</b> In a thorough QT study described in the macimorelin prescribing information, macimorelin (2 mg/kg [4 times the recommended dosage]) increased the mean (upper single-sided 95% confidence interval) QTc interval 9.6 msec (11.4 msec) at 4 hours post-dose, which occurred after the mean maximum macimorelin plasma concentration (0.5 hours).<sup>1</sup> A similar increase in the QTc interval was also observed in a single-ascending dose study, which included three dose levels (0.5 mg/kg, 1 mg/kg and 2 mg/kg). All three doses levels studied showed a similar magnitude of QTc prolongation that was seen in the thorough QT study, suggesting an absence of dose dependent changes.<sup>1</sup><br><br>Macimorelin prescribing information states that because macimorelin may prolong the QT interval, concomitant use with other drugs known to prolong the QT interval should be avoided.<sup>1</sup> Concomitant use may result in torsade de pointes.<sup>1</sup> A sufficient washout period should be provided after discontinuation of drugs that prolong the QT interval prior to macimorelin administration.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Macrelin (macimorelin) [prescribing information]. Frankfurt am Main, Germany; Aeterna Zentaris GmbH: December 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11828":"<p><b>Title</b> QTc-Prolonging Agents (Moderate Risk) / Macimorelin</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Macimorelin may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk). <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Avoid concomitant use of macimorelin and drugs that prolong the QT interval. A sufficient washout period should be provided after discontinuation of drugs that prolong the QT interval prior to macimorelin administration.</p>\n<div>\n <p><b>QTc-Prolonging Agents (Moderate Risk) Interacting Members</b> Azithromycin (Systemic), Bedaquiline, Benperidol, Ceritinib, Chloroquine, ChlorproMAZINE, Ciprofloxacin (Systemic), Clarithromycin, Clofazimine, CloZAPine, Crizotinib, Delamanid, Dolasetron, Droperidol, Efavirenz, Erythromycin (Systemic), Escitalopram, Flecainide, Gadobenate Dimeglumine, Gemifloxacin, Goserelin, Granisetron, Haloperidol, Inotuzumab Ozogamicin, Lenvatinib, Leuprolide, LevoFLOXacin (Oral Inhalation), LevoFLOXacin (Systemic), Lofexidine, Mequitazine, Methadone, Midostaurin, Moxifloxacin (Systemic), Ofloxacin (Systemic), OLANZapine, Ondansetron, Osimertinib, Panobinostat, PAZOPanib, Pentamidine (Systemic), Pilsicainide, Piperaquine, Primaquine, Probucol, Propafenone, RisperiDONE, Roxithromycin, Saquinavir, Sodium Stibogluconate, Telavancin, Telithromycin, Terlipressin</p>\n</div> \n<p><b>Discussion</b> In a thorough QT study described in the macimorelin prescribing information, macimorelin (2 mg/kg [4 times the recommended dosage]) increased the mean (upper single-sided 95% confidence interval) QTc interval 9.6 msec (11.4 msec) at 4 hours post-dose, which occurred after the mean maximum macimorelin plasma concentration (0.5 hours).<sup>1</sup> A similar increase in the QTc interval was also observed in a single-ascending dose study, which included three dose levels (0.5 mg/kg, 1 mg/kg and 2 mg/kg). All three doses levels studied showed a similar magnitude of QTc prolongation that was seen in the thorough QT study, suggesting an absence of dose dependent changes.<sup>1</sup><br><br>Macimorelin prescribing information states that because macimorelin may prolong the QT interval, concomitant use with other drugs known to prolong the QT interval should be avoided.<sup>1</sup> Concomitant use may result in torsade de pointes.<sup>1</sup> A sufficient washout period should be provided after discontinuation of drugs that prolong the QT interval prior to macimorelin administration.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Macrelin (macimorelin) [prescribing information]. Frankfurt am Main, Germany; Aeterna Zentaris GmbH: December 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11829":"<p><b>Title</b> Macimorelin / Somatostatin Analogs</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Somatostatin Analogs may diminish the diagnostic effect of Macimorelin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid concomitant use of macimorelin and drugs that directly affect the pituitary secretion of growth hormone (eg, somatostatin, insulin, glucocorticoids, cyclooxygenase inhibitors).</p>\n<div>\n <p><b>Somatostatin Analogs Interacting Members</b> Lanreotide, Octreotide, Pasireotide, Somatostatin Acetate</p>\n</div> \n<p><b>Discussion</b> The macimorelin prescribing information states that drugs that directly affect the pituitary secretion of growth hormone (eg, somatostatin, insulin, glucocorticoids, cyclooxygenase inhibitors) may impact the accuracy of the macimorelin diagnostic test.<sup>1</sup> Concomitant use of macimorelin and these agents should be avoided and a sufficient washout period should be provided after discontinuation of these drugs prior to macimorelin administration.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Macrelin (macimorelin) [prescribing information]. Frankfurt am Main, Germany; Aeterna Zentaris GmbH: December 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11830":"<p><b>Title</b> Macimorelin / Insulins</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Insulins may diminish the diagnostic effect of Macimorelin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid concomitant use of macimorelin and drugs that directly affect the pituitary secretion of growth hormone (eg, somatostatin, insulin, glucocorticoids, cyclooxygenase inhibitors).</p>\n<div>\n <p><b>Insulins Interacting Members</b> Insulin (Oral Inhalation), Insulin Aspart, Insulin Degludec, Insulin Detemir, Insulin Glargine, Insulin Glulisine, Insulin Lispro, Insulin NPH, Insulin Regular</p>\n</div> \n<p><b>Discussion</b> The macimorelin prescribing information states that drugs that directly affect the pituitary secretion of growth hormone (eg, somatostatin, insulin, glucocorticoids, cyclooxygenase inhibitors) may impact the accuracy of the macimorelin diagnostic test.<sup>1</sup> Concomitant use of macimorelin and these agents should be avoided and a sufficient washout period should be provided after discontinuation of these drugs prior to macimorelin administration.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Macrelin (macimorelin) [prescribing information]. Frankfurt am Main, Germany; Aeterna Zentaris GmbH: December 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11831":"<p><b>Title</b> Macimorelin / Corticosteroids (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Corticosteroids (Systemic) may diminish the diagnostic effect of Macimorelin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid concomitant use of macimorelin and drugs that directly affect the pituitary secretion of growth hormone (eg, somatostatin, insulin, glucocorticoids, cyclooxygenase inhibitors).</p>\n<div>\n <p><b>Corticosteroids (Systemic) Interacting Members</b> Beclomethasone (Systemic), Betamethasone (Systemic), Corticotropin, Cortisone, Deflazacort, Dexamethasone (Systemic), Fludrocortisone, Hydrocortisone (Systemic), MethylPREDNISolone, PrednisoLONE (Systemic), PredniSONE, Triamcinolone (Systemic)</p>\n</div> \n<p><b>Discussion</b> The macimorelin prescribing information states that drugs that directly affect the pituitary secretion of growth hormone (eg, somatostatin, insulin, glucocorticoids, cyclooxygenase inhibitors) may impact the accuracy of the macimorelin diagnostic test.<sup>1</sup> Concomitant use of macimorelin and these agents should be avoided and a sufficient washout period should be provided after discontinuation of these drugs prior to macimorelin administration.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Macrelin (macimorelin) [prescribing information]. Frankfurt am Main, Germany; Aeterna Zentaris GmbH: December 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11832":"<p><b>Title</b> Macimorelin / Aspirin</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Aspirin may diminish the diagnostic effect of Macimorelin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid concomitant use of macimorelin and drugs that directly affect the pituitary secretion of growth hormone (eg, somatostatin, insulin, glucocorticoids, cyclooxygenase inhibitors).</p> \n<p><b>Discussion</b> The macimorelin prescribing information states that drugs that directly affect the pituitary secretion of growth hormone (eg, somatostatin, insulin, glucocorticoids, cyclooxygenase inhibitors) may impact the accuracy of the macimorelin diagnostic test.<sup>1</sup> Concomitant use of macimorelin and these agents should be avoided and a sufficient washout period should be provided after discontinuation of these drugs prior to macimorelin administration.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Macrelin (macimorelin) [prescribing information]. Frankfurt am Main, Germany; Aeterna Zentaris GmbH: December 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11833":"<p><b>Title</b> Macimorelin / Nonsteroidal Anti-Inflammatory Agents</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Nonsteroidal Anti-Inflammatory Agents may diminish the diagnostic effect of Macimorelin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid concomitant use of macimorelin and drugs that directly affect the pituitary secretion of growth hormone (eg, somatostatin, insulin, glucocorticoids, cyclooxygenase inhibitors).</p>\n<div>\n <p><b>Nonsteroidal Anti-Inflammatory Agents Interacting Members</b> Aceclofenac, Acemetacin, Celecoxib, Dexibuprofen, Dexketoprofen, Diclofenac (Systemic), Diclofenac (Topical), Diflunisal, Dipyrone, Etodolac, Etofenamate, Etoricoxib, Fenoprofen, Floctafenine, Flurbiprofen (Systemic), Ibuprofen, Ibuprofen (Topical), Indomethacin, Ketoprofen, Ketorolac (Nasal), Ketorolac (Systemic), Lornoxicam, Loxoprofen, Meclofenamate, Mefenamic Acid, Meloxicam, Morniflumate, Nabumetone, Naproxen, Nimesulide, Oxaprozin, Parecoxib, Pelubiprofen, Phenylbutazone, Piroxicam (Systemic), Piroxicam (Topical), Propyphenazone, Sulindac, Talniflumate, Tenoxicam, Tiaprofenic Acid, Tolfenamic Acid, Tolmetin, Zaltoprofen</p>\n</div> \n<p><b>Discussion</b> The macimorelin prescribing information states that drugs that directly affect the pituitary secretion of growth hormone (eg, somatostatin, insulin, glucocorticoids, cyclooxygenase inhibitors) may impact the accuracy of the macimorelin diagnostic test.<sup>1</sup> Concomitant use of macimorelin and these agents should be avoided and a sufficient washout period should be provided after discontinuation of these drugs prior to macimorelin administration.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Macrelin (macimorelin) [prescribing information]. Frankfurt am Main, Germany; Aeterna Zentaris GmbH: December 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11834":"<p><b>Title</b> Macimorelin / CloNIDine</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> CloNIDine may diminish the diagnostic effect of Macimorelin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid concomitant use of macimorelin and drugs that may transiently elevate growth hormone concentrations (eg, clonidine, levodopa, insulin).</p> \n<p><b>Discussion</b> Macimorelin prescribing information states that drugs that may transiently elevate growth hormone concentrations (such as clonidine, levodopa, and insulin) may impact the accuracy of the macimorelin diagnostic test.<sup>1</sup> Concomitant use of macimorelin and these agents should be avoided and a sufficient washout period should be provided after discontinuation of these drugs prior to macimorelin administration.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Macrelin (macimorelin) [prescribing information]. Frankfurt am Main, Germany; Aeterna Zentaris GmbH: December 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11835":"<p><b>Title</b> Macimorelin / Levodopa</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Levodopa may diminish the diagnostic effect of Macimorelin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid concomitant use of macimorelin and drugs that may transiently elevate growth hormone concentrations (eg, clonidine, levodopa, insulin).</p> \n<p><b>Discussion</b> Macimorelin prescribing information states that drugs that may transiently elevate growth hormone concentrations (such as clonidine, levodopa, and insulin) may impact the accuracy of the macimorelin diagnostic test.<sup>1</sup> Concomitant use of macimorelin and these agents should be avoided and a sufficient washout period should be provided after discontinuation of these drugs prior to macimorelin administration.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Macrelin (macimorelin) [prescribing information]. Frankfurt am Main, Germany; Aeterna Zentaris GmbH: December 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11836":"<p><b>Title</b> Macimorelin / Atropine (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Atropine (Systemic) may diminish the diagnostic effect of Macimorelin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid concomitant use of macimorelin and drugs that may blunt the growth hormone response to macimorelin (eg, atropine, propylthiouracil, growth hormone products).</p> \n<p><b>Discussion</b> The macimorelin prescribing information states that drugs that may blunt the growth hormone response to macimorelin (eg, atropine, propylthiouracil, growth hormone products) may impact the accuracy of the macimorelin diagnostic test.<sup>1</sup> Concomitant use of macimorelin and these agents should be avoided and a sufficient washout period should be provided after discontinuation of these drugs prior to macimorelin administration.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Macrelin (macimorelin) [prescribing information]. Frankfurt am Main, Germany; Aeterna Zentaris GmbH: December 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11837":"<p><b>Title</b> Macimorelin / Propylthiouracil</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Propylthiouracil may diminish the diagnostic effect of Macimorelin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid concomitant use of macimorelin and drugs that may blunt the growth hormone response to macimorelin (eg, atropine, propylthiouracil, growth hormone products).</p> \n<p><b>Discussion</b> The macimorelin prescribing information states that drugs that may blunt the growth hormone response to macimorelin (eg, atropine, propylthiouracil, growth hormone products) may impact the accuracy of the macimorelin diagnostic test.<sup>1</sup> Concomitant use of macimorelin and these agents should be avoided and a sufficient washout period should be provided after discontinuation of these drugs prior to macimorelin administration.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Macrelin (macimorelin) [prescribing information]. Frankfurt am Main, Germany; Aeterna Zentaris GmbH: December 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11838":"<p><b>Title</b> Macimorelin / Growth Hormone Products</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Growth Hormone Products may diminish the diagnostic effect of Macimorelin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid concomitant use of macimorelin and drugs that may blunt the growth hormone response to macimorelin (eg, atropine, propylthiouracil, growth hormone products). Discontinue growth hormone products at least one week before administering the macimorelin diagnostic test.</p>\n<div>\n <p><b>Growth Hormone Products Interacting Members</b> Macimorelin, Mecasermin, Pegvisomant, Somatropin, Tesamorelin</p>\n</div> \n<p><b>Discussion</b> The macimorelin prescribing information states that drugs that may blunt the growth hormone response to macimorelin (eg, atropine, propylthiouracil, growth hormone products) may impact the accuracy of the macimorelin diagnostic test.<sup>1</sup> Concomitant use of macimorelin and growth hormone products should be avoided. Discontinue growth hormone products at least one week before administering the macimorelin diagnostic test.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Macrelin (macimorelin) [prescribing information]. Frankfurt am Main, Germany; Aeterna Zentaris GmbH: December 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11839":"<p><b>Title</b> Macimorelin / St John's Wort</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> St John's Wort may decrease the serum concentration of Macimorelin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Discontinue St. John's wort prior to macimorelin use. A sufficient washout period should be provided after discontinuation of St. John's wort prior to macimorelin administration. Concomitant use may lead to false positive test results.</p> \n<p><b>Discussion</b> The macimorelin prescribing information states that because macimorelin is metabolized by CYP3A4, use of CYP3A4 inducers (ie, St. John's wort) may reduce the plasma macimorelin concentrations and may lead to false positive test results.<sup>1</sup> St. John's wort should be discontinued prior to macimorelin use and a sufficient washout period should be provided after discontinuation prior to macimorelin administration.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Macrelin (macimorelin) [prescribing information]. Frankfurt am Main, Germany; Aeterna Zentaris GmbH: December 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11846":"<p><b>Title</b> Macimorelin / Bosentan</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Bosentan may diminish the diagnostic effect of Macimorelin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for reduced macimorelin effectiveness and the possibility of a false positive test if combined with bosentan.</p> \n<p><b>Discussion</b> The macimorelin prescribing information states that because macimorelin is metabolized by CYP3A4, use of strong CYP3A4 inducers may reduce the plasma macimorelin concentrations and may lead to false positive test results.<sup>1</sup> Strong CYP3A4 inducers should be discontinued prior to macimorelin use and a sufficient washout period should be provided after discontinuation of strong CYP3A4 inducers prior to macimorelin administration.<sup>1</sup> Although the prescribing information lists bosentan, efavirenz, etravirine and modafinil as examples of strong CYP3A4 inducers, the majority of clinical data suggest that these drugs are moderate CYP3A4 inducers.<sup>2,3,4,5,6</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Macrelin (macimorelin) [prescribing information]. Frankfurt am Main, Germany; Aeterna Zentaris GmbH: December 2017.</p>\n<p>2. Tracleer (bosentan) [prescribing information]. South San Francisco, CA: Actelion Pharmaceuticals US Inc; September 2017.</p>\n<p>3. Sustiva (efavirenz) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; October 2017.</p>\n<p>4. Intelence (etravirine) [prescribing information]. Titusville NJ: Janssen Therapeutics; August 2014.</p>\n<p>5. Kakuda TN, Abel S, Davis J, et al. Pharmacokinetic interactions of maraviroc with darunavir-ritonavir, etravirine, and etravirine-darunavir-ritonavir in healthy volunteers: results of two drug interaction trials. <i>Antimicrob Agents Chemother</i>. 2011;55(5):2290-2296. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21383098\">[PubMed 21383098]</a></p>\n<p>6. Robertson P Jr, Hellriegel ET, Arora S, Nelson M. Effect of modafinil on the pharmacokinetics of ethinyl estradiol and triazolam in healthy volunteers. <i>Clin Pharmacol Ther</i>. 2002;71(1):46-56. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11823757\">[PubMed 11823757]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11847":"<p><b>Title</b> Macimorelin / Etravirine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Etravirine may diminish the diagnostic effect of Macimorelin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for reduced macimorelin effectiveness and the possibility of a false positive test if combined with etravirine.</p> \n<p><b>Discussion</b> The macimorelin prescribing information states that because macimorelin is metabolized by CYP3A4, use of strong CYP3A4 inducers may reduce the plasma macimorelin concentrations and may lead to false positive test results.<sup>1</sup> Strong CYP3A4 inducers should be discontinued prior to macimorelin use and a sufficient washout period should be provided after discontinuation of strong CYP3A4 inducers prior to macimorelin administration.<sup>1</sup> Although the prescribing information lists bosentan, efavirenz, etravirine and modafinil as examples of strong CYP3A4 inducers, the majority of clinical data suggest that these drugs are moderate CYP3A4 inducers.<sup>2,3,4,5,6</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Macrelin (macimorelin) [prescribing information]. Frankfurt am Main, Germany; Aeterna Zentaris GmbH: December 2017.</p>\n<p>2. Tracleer (bosentan) [prescribing information]. South San Francisco, CA: Actelion Pharmaceuticals US Inc; September 2017.</p>\n<p>3. Sustiva (efavirenz) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; October 2017.</p>\n<p>4. Intelence (etravirine) [prescribing information]. Titusville NJ: Janssen Therapeutics; August 2014.</p>\n<p>5. Kakuda TN, Abel S, Davis J, et al. Pharmacokinetic interactions of maraviroc with darunavir-ritonavir, etravirine, and etravirine-darunavir-ritonavir in healthy volunteers: results of two drug interaction trials. <i>Antimicrob Agents Chemother</i>. 2011;55(5):2290-2296. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21383098\">[PubMed 21383098]</a></p>\n<p>6. Robertson P Jr, Hellriegel ET, Arora S, Nelson M. Effect of modafinil on the pharmacokinetics of ethinyl estradiol and triazolam in healthy volunteers. <i>Clin Pharmacol Ther</i>. 2002;71(1):46-56. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11823757\">[PubMed 11823757]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11848":"<p><b>Title</b> Macimorelin / Efavirenz</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Efavirenz may diminish the diagnostic effect of Macimorelin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for reduced macimorelin effectiveness and the possibility of a false positive test if combined with efavirenz.</p> \n<p><b>Discussion</b> The macimorelin prescribing information states that because macimorelin is metabolized by CYP3A4, use of strong CYP3A4 inducers may reduce the plasma macimorelin concentrations and may lead to false positive test results.<sup>1</sup> Strong CYP3A4 inducers should be discontinued prior to macimorelin use and a sufficient washout period should be provided after discontinuation of strong CYP3A4 inducers prior to macimorelin administration.<sup>1</sup> Although the prescribing information lists bosentan, efavirenz, etravirine and modafinil as examples of strong CYP3A4 inducers, the majority of clinical data suggest that these drugs are moderate CYP3A4 inducers.<sup>2,3,4,5,6</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Macrelin (macimorelin) [prescribing information]. Frankfurt am Main, Germany; Aeterna Zentaris GmbH: December 2017.</p>\n<p>2. Tracleer (bosentan) [prescribing information]. South San Francisco, CA: Actelion Pharmaceuticals US Inc; September 2017.</p>\n<p>3. Sustiva (efavirenz) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; October 2017.</p>\n<p>4. Intelence (etravirine) [prescribing information]. Titusville NJ: Janssen Therapeutics; August 2014.</p>\n<p>5. Kakuda TN, Abel S, Davis J, et al. Pharmacokinetic interactions of maraviroc with darunavir-ritonavir, etravirine, and etravirine-darunavir-ritonavir in healthy volunteers: results of two drug interaction trials. <i>Antimicrob Agents Chemother</i>. 2011;55(5):2290-2296. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21383098\">[PubMed 21383098]</a></p>\n<p>6. Robertson P Jr, Hellriegel ET, Arora S, Nelson M. Effect of modafinil on the pharmacokinetics of ethinyl estradiol and triazolam in healthy volunteers. <i>Clin Pharmacol Ther</i>. 2002;71(1):46-56. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11823757\">[PubMed 11823757]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11849":"<p><b>Title</b> Macimorelin / Modafinil</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Modafinil may diminish the diagnostic effect of Macimorelin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for reduced macimorelin effectiveness and the possibility of a false positive test if combined with modafinil.</p> \n<p><b>Discussion</b> The macimorelin prescribing information states that because macimorelin is metabolized by CYP3A4, use of strong CYP3A4 inducers may reduce the plasma macimorelin concentrations and may lead to false positive test results.<sup>1</sup> Strong CYP3A4 inducers should be discontinued prior to macimorelin use and a sufficient washout period should be provided after discontinuation of strong CYP3A4 inducers prior to macimorelin administration.<sup>1</sup> Although the prescribing information lists bosentan, efavirenz, etravirine and modafinil as examples of strong CYP3A4 inducers, the majority of clinical data suggest that these drugs are moderate CYP3A4 inducers.<sup>2,3,4,5,6</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Macrelin (macimorelin) [prescribing information]. Frankfurt am Main, Germany; Aeterna Zentaris GmbH: December 2017.</p>\n<p>2. Tracleer (bosentan) [prescribing information]. South San Francisco, CA: Actelion Pharmaceuticals US Inc; September 2017.</p>\n<p>3. Sustiva (efavirenz) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; October 2017.</p>\n<p>4. Intelence (etravirine) [prescribing information]. Titusville NJ: Janssen Therapeutics; August 2014.</p>\n<p>5. Kakuda TN, Abel S, Davis J, et al. Pharmacokinetic interactions of maraviroc with darunavir-ritonavir, etravirine, and etravirine-darunavir-ritonavir in healthy volunteers: results of two drug interaction trials. <i>Antimicrob Agents Chemother</i>. 2011;55(5):2290-2296. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21383098\">[PubMed 21383098]</a></p>\n<p>6. Robertson P Jr, Hellriegel ET, Arora S, Nelson M. Effect of modafinil on the pharmacokinetics of ethinyl estradiol and triazolam in healthy volunteers. <i>Clin Pharmacol Ther</i>. 2002;71(1):46-56. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11823757\">[PubMed 11823757]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11850":"<p><b>Title</b> Macimorelin / Armodafinil</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Armodafinil may diminish the diagnostic effect of Macimorelin. <b>Severity</b> Minor <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> The macimorelin prescribing information states that because macimorelin is metabolized by CYP3A4, use of strong CYP3A4 inducers may reduce the plasma macimorelin concentrations and may lead to false positive test results.<sup>1</sup> Strong CYP3A4 inducers should be discontinued prior to macimorelin use and a sufficient washout period should be provided after discontinuation of strong CYP3A4 inducers prior to macimorelin administration.<sup>1</sup> Although the prescribing information lists armodafinil and rufinamide as examples of strong CYP3A4 inducers, the majority of clinical data suggest that these drugs are weak CYP3A4 inducers.<sup>2,3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Macrelin (macimorelin) [prescribing information]. Frankfurt am Main, Germany; Aeterna Zentaris GmbH: December 2017.</p>\n<p>2. Darwish M, Kirby M, Robertson P Jr, Hellriegel ET. Interaction profile of armodafinil with medications metabolized by cytochrome P450 enzymes 1A2, 3A4 and 2C19 in healthy subjects. <i>Clin Pharmacokinet</i>. 2008;47(1):61-74. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18076219\">[PubMed 18076219]</a></p>\n<p>3. Banzel (rufinamide) [prescribing information]. Woodcliff Lake, NJ: Eisai Inc; June 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11851":"<p><b>Title</b> Macimorelin / Rufinamide</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Rufinamide may diminish the diagnostic effect of Macimorelin. <b>Severity</b> Minor <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> The macimorelin prescribing information states that because macimorelin is metabolized by CYP3A4, use of strong CYP3A4 inducers may reduce the plasma macimorelin concentrations and may lead to false-positive test results.<sup>1</sup> Strong CYP3A4 inducers should be discontinued prior to macimorelin use and a sufficient washout period should be provided after discontinuation of strong CYP3A4 inducers prior to macimorelin administration.<sup>1</sup> Although the prescribing information lists armodafinil and rufinamide as examples of strong CYP3A4 inducers, the majority of clinical data suggest that these drugs are weak CYP3A4 inducers.<sup>2,3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Macrelin (macimorelin) [prescribing information]. Frankfurt am Main, Germany; Aeterna Zentaris GmbH: December 2017.</p>\n<p>2. Darwish M, Kirby M, Robertson P Jr, Hellriegel ET. Interaction profile of armodafinil with medications metabolized by cytochrome P450 enzymes 1A2, 3A4 and 2C19 in healthy subjects. <i>Clin Pharmacokinet</i>. 2008;47(1):61-74. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18076219\">[PubMed 18076219]</a></p>\n<p>3. Banzel (rufinamide) [prescribing information]. Woodcliff Lake, NJ: Eisai Inc; June 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11852":"<p><b>Title</b> Dapsone (Systemic) / Rifabutin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Rifabutin may decrease the serum concentration of Dapsone (Systemic). <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for reduced dapsone effectiveness if combined with rifabutin.</p> \n<p><b>Discussion</b> In a pharmacokinetic study of 12 patients with HIV, rifabutin (300 mg daily for 14 days) decreased the dapsone (100 mg daily for 14 days) AUC 36% and increased the dapsone clearance 67%.<sup>1</sup> In a pharmacokinetic study described in the rifabutin prescribing information, rifabutin (300 mg daily) decreased the dapsone (50 mg daily) AUC 27% to 40% in 16 patients with HIV.<sup>2</sup><br><br>The mechanism of this interaction has not been fully investigated, but rifabutin-mediated induction of the CYP isoenzymes involved in dapsone metabolism (ie, CYP3A4, CYP2C) likely contributes.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Winter HR, Trapnell CB, Slattery JT, et al. The effect of clarithromycin, fluconazole, and rifabutin on dapsone hydroxylamine formation in individuals with human immunodeficiency virus infection (AACTG 283). <i>Clin Pharmacol Ther</i>. 2004;76(6):579-587. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15592329\">[PubMed 15592329]</a></p>\n<p>2. Mycobutin (rifabutin) [prescribing information]. New York, NY: Pfizer Inc; May 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11853":"<p><b>Title</b> Sulfamethoxazole / Rifabutin</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Rifabutin may decrease the serum concentration of Sulfamethoxazole. Additionally, rifabutin my increase the formation of a toxic sulfamethoxazole metabolite (sulfamethoxazole hydroxylamine) <b>Severity</b> Minor <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> In a pharmacokinetic study of 9 patients with HIV, coadministration of rifabutin (300 mg daily for 14 days) and sulfamethoxazole/trimethoprim (800 mg/160 mg daily for 14 days) had no effect on the sulfamethoxazole AUC, but did increase the AUC of the sulfamethoxazole-hydroxylamine metabolite (thought possibly to be responsible for the majority of sulfamethoxazole toxicities) 57%.<sup>1</sup> In a pharmacokinetic study described in the rifabutin prescribing information, the sulfamethoxazole AUC decreased 15% to 20% when rifabutin (300 mg daily) was coadministered with sulfamethoxazole/trimethoprim (800 mg/160 mg) in 12 patients with HIV.<sup>2</sup><br><br>The mechanism of this interaction has not been fully investigated, but rifabutin-mediated induction of the CYP3A4 and/or CYP2C isoenzymes responsible for sulfamethoxazole metabolism likely contributes.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Winter HR, Trapnell CB, Slattery JT, et al. The effect of clarithromycin, fluconazole, and rifabutin on sulfamethoxazole hyroxylamine formation in individuals with human immunodeficiency virus infection (AACTG 283). <i>Clin Pharmacol Ther</i>. 2004;76(4):313-322. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15470330\">[PubMed 15470330]</a></p>\n<p>2. Mycobutin (rifabutin) [prescribing information]. New York, NY: Pfizer Inc; May 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11854":"<p><b>Title</b> Indinavir / Rifapentine</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Rifapentine may decrease the serum concentration of Indinavir. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Consider avoiding the combination of indinavir and rifapentine whenever possible due to the risk for decreased indinavir concentrations, reduced efficacy, and development of resistance. If combined, monitor for indinavir treatment failure.</p> \n<p><b>Discussion</b> In a pharmacokinetic study described in the rifapentine prescribing information, rifapentine (600 mg twice a week for 14 days) decreased the indinavir (800 mg three times daily for 14 days) AUC and maximum serum concentration 70% and 55%, respectively.<sup>1</sup> Indinavir clearance increased 3-fold and the pharmacokinetics of rifapentine were unchanged.<sup>1</sup><br><br>Rifapentine prescribing information states that because rifapentine is an inducer of CYP3A4, it may increase the metabolism and decrease the activity of drugs that are metabolized by CYP3A4.<sup>1</sup> Indinavir prescribing information does not provide a recommendation for use with rifapentine, but does contraindicate use with rifampin, another rifamycin derivative that has been shown to decrease indinavir exposure by more than 90%.<sup>2</sup><br><br>The mechanism of this interaction is likely due to rifapentine-mediated induction of CYP3A4, an enzyme responsible for indinavir metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Priftin (rifapentine) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis US LLC; November 2014.</p>\n<p>2. Crixivan (indinavir) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co Inc; September 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11855":"<p><b>Title</b> Ranolazine / Rifabutin</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Rifabutin may decrease the serum concentration of Ranolazine. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid the concomitant use of ranolazine and rifabutin. Use of ranolazine and CYP3A4 inducers is listed as a contraindication in the ranolazine prescribing information.</p> \n<p><b>Discussion</b> Data described in the ranolazine product labeling show that coadministration of the strong CYP3A4 inducer rifampin (600 mg daily) and ranolazine (1,000 mg twice daily) resulted in a 95% decrease in ranolazine plasma concentrations.<sup>1</sup> Although studies with the weak CYP3A inducer rifabutin have not yet been conducted, product labeling recommends avoiding the concomitant use of ranolazine and rifabutin<sup>1</sup><br><br>Although the mechanism of this interaction has not been fully established, it is suspected that induction of CYP3A-mediated metabolism of ranolazine by rifampin (or other inducers) is primarily responsible.<sup>1</sup> Induction of P-glycoprotein-mediated transport (resulting in impaired absorption and enhanced elimination) of ranolazine by rifampin (or other inducers) has also been mentioned as a possible contributing mechanism.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Ranexa (ranolazine) [prescribing information]. Foster City, CA: Gilead Sciences Inc; December 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11856":"<p><b>Title</b> Bedaquiline / Rifabutin</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Rifabutin may enhance the adverse/toxic effect of Bedaquiline. Rifabutin may decrease the serum concentration of Bedaquiline. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid concomitant of bedaquiline and rifabutin.</p> \n<p><b>Discussion</b> In a pharmacokinetic study of 14 healthy volunteers, rifabutin (300 mg daily for 21 days) had negligible effects on the bedaquiline (400 mg single dose) pharmacokinetic parameters.<sup>1</sup> However, adverse event rates were significantly higher during coadministration with rifabutin compared with rates during treatment with bedaquiline alone (17% vs 76%; p = 0.0063).<sup>1</sup> In a clinical study summarized in bedaquiline prescribing information, coadministration with another rifamycin derivative, rifampin (600 mg daily for 21 days), decreased the bedaquiline (300 mg) AUC by 52% in healthy volunteers.<sup>2</sup> In another pharmacokinetic study of 28 healthy volunteers, bedaquiline (400 mg single oral dose) was administered before and after a 22-day course of rifampin (600 mg once daily) or rifapentine (600 mg once daily).<sup>3</sup> Rifampin decreased the bedaquiline AUC and maximum serum concentration (Cmax) 53% and 40%, respectively, and rifapentine reduced the bedaquiline AUC 55% and Cmax 38%.<sup>3</sup> In an open-label phase 1 study, the bedaquiline clearance increased by an average of 478% with rifampin and 389% with rifapentine.<sup>4</sup> <br><br>Bedaquiline prescribing information states that coadministration of bedaquiline and rifamycins should be avoided due to the risk of decreased systemic exposure and reduced therapeutic efficacy.<sup>2</sup> It should be noted that although the bedaquiline prescribing information states coadministration with all rifamycins should be avoided, rifabutin appears to be a weak CYP3A4 inducer, while rifampin and rifapentine appear to be a strong CYP3A4 inducer and a moderate CYP3A4 inducer, respectively.<sup>5,6,7</sup> <br><br>The suspected primary mechanism of this interaction is increased CYP3A4-mediated bedaquiline metabolism by CYP3A4 inducers such as rifampin or rifapentine. The mechanism behind an increased risk of adverse events with this combination is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Healan AM, Griffiss JM, Proskin HM, et al. Impact of rifabutin or rifampin on bedaquiline safety, tolerability, and pharmacokinetics assessed in a randomized clinical trial with healthy adult volunteers. <i>Antimicrob Agents Chemother</i>. 2017;62(1):pii:e00855-17. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=29061739\">[PubMed 29061739]</a></p>\n<p>2. Sirturo (bedaquiline) [prescribing information]. Titusville, NJ: Janssen Products LP; May 2015.</p>\n<p>3. Winter H, Egizi E, Murray S, et al. Evaluation of the pharmacokinetic interaction between repeated doses of rifapentine or rifampin and a single dose of bedaquiline in healthy adult subjects. <i>Antimicrob Agents Chemother</i>. 2015;59(2):1219-1224. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25512422\">[PubMed 25512422]</a></p>\n<p>4. Svensson EM, Murray S, Karlsson MO, Dooley KE. Rifampicin and rifapentine significantly reduce concentrations of bedaquiline, a new anti-TB drug. <i>J Antimicrob Chemother</i>. 2015;70(4):1106-1114. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25535219\">[PubMed 25535219]</a></p>\n<p>5. Villikka K, Kivisto KT, Backman JT, Olkkola KT, Neuvonen PJ. Triazolam is ineffective in patients taking rifampin. <i>Clin Pharmacol Ther</i>. 1997;61(1):8-14. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9024169\">[PubMed 9024169]</a></p>\n<p>6. Mycobutin (rifabutin) [prescribing information]. New York, NY: Pfizer Inc; May 2015.</p>\n<p>7. Priftin (rifapentine) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis US LLC; November 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11857":"<p><b>Title</b> Erlotinib / Rifapentine</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Rifapentine may decrease the serum concentration of Erlotinib. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid concomitant use of erlotinib with rifabutin when possible. If such a combination cannot be avoided, the erlotinib prescribing information recommends increasing the erlotinib dose by 50 mg increments at 2 week intervals as tolerated, to a maximum of 450 mg/day.</p> \n<p><b>Discussion</b> The erlotinib AUC was reduced by an average of 67% to 81% with concomitant administration of rifampin (600 mg/day for 7 to 11 days), a strong CYP3A4 inducer, in two separate studies in healthy volunteers.<sup>1</sup> Similarly, an in vitro study conducted in cultured hepatocytes found that clearance of erlotinib was increased approximately 2-fold by rifampin and the moderate CYP3A4 inducer efavirenz.<sup>2</sup> Although rifapentine is often considered a moderate CYP3A4 inducer,<sup>3</sup> the erlotinib prescribing information recommends avoiding this combination when possible, and when the combination must be used, increasing the erlotinib dose by 50 mg increments at 2 week intervals as tolerated, to a maximum of 450 mg/day.<sup>4</sup><br><br>The likely mechanism for this interaction is increased CYP3A-mediated metabolism of erlotinib, as erlotinib metabolism is primarily mediated by CYP3A4 with some additional contribution by CYP1A2.<sup>4</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Hamilton M, Wolf JL, Drolet DW, et al. The effect of rifampicin, a prototypical CYP3A4 inducer, on erlotinib pharmacokinetics in healthy subjects. <i>Cancer Chemother Pharmacol</i>. 2014;73(3):613-621. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24474302\">[PubMed 24474302]</a></p>\n<p>2. Pillai VC, Venkataramanan R, Parise RA, et al. Ritonavir and efavirenz significantly alter the metabolism of erlotinib--an observation in primary cultures of human hepatocytes that is relevant to HIV patients with cancer. <i>Drug Metab Dispos</i>. 2013;41(10):1843-1851. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23913028\">[PubMed 23913028]</a></p>\n<p>3. Priftin (rifapentine) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis US LLC; November 2014.</p>\n<p>4. Tarceva (erlotinib) [prescribing information]. Northbrook, IL: OSI Pharmaceuticals LLC; October 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11858":"<p><b>Title</b> Erlotinib / Rifabutin</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Rifabutin may decrease the serum concentration of Erlotinib. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid concomitant use of erlotinib with rifabutin when possible. If such a combination cannot be avoided, the erlotinib prescribing information recommends increasing the erlotinib dose by 50 mg increments at 2 week intervals as tolerated, to a maximum of 450 mg/day.</p> \n<p><b>Discussion</b> The erlotinib AUC was reduced by an average of 67% to 81% with concomitant administration of rifampin (600 mg/day for 7 to 11 days), a strong CYP3A4 inducer, in two separate studies in healthy volunteers.<sup>1</sup> Similarly, an in vitro study conducted in cultured hepatocytes found that clearance of erlotinib was increased approximately 2-fold by rifampin and the moderate CYP3A4 inducer efavirenz.<sup>2</sup> Although rifabutin is often considered a weak CYP3A4 inducer,<sup>3</sup> the erlotinib prescribing information recommends avoiding this combination when possible, and when the combination must be used, increasing the erlotinib dose by 50 mg increments at 2 week intervals as tolerated, to a maximum of 450 mg/day.<sup>4</sup><br><br>The likely mechanism for this interaction is increased CYP3A-mediated metabolism of erlotinib, as erlotinib metabolism is primarily mediated by CYP3A4 with some additional contribution by CYP1A2.<sup>4</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Hamilton M, Wolf JL, Drolet DW, et al. The effect of rifampicin, a prototypical CYP3A4 inducer, on erlotinib pharmacokinetics in healthy subjects. <i>Cancer Chemother Pharmacol</i>. 2014;73(3):613-621. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24474302\">[PubMed 24474302]</a></p>\n<p>2. Pillai VC, Venkataramanan R, Parise RA, et al. Ritonavir and efavirenz significantly alter the metabolism of erlotinib--an observation in primary cultures of human hepatocytes that is relevant to HIV patients with cancer. <i>Drug Metab Dispos</i>. 2013;41(10):1843-1851. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23913028\">[PubMed 23913028]</a></p>\n<p>3. Mycobutin (rifabutin) [prescribing information]. New York, NY: Pfizer Inc; May 2015.</p>\n<p>4. Tarceva (erlotinib) [prescribing information]. Northbrook, IL: OSI Pharmaceuticals LLC; October 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11859":"<p><b>Title</b> Sirolimus / Rifabutin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Rifabutin may decrease the serum concentration of Sirolimus. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for decreased sirolimus concentrations and effects if combined with rifabutin.</p> \n<p><b>Discussion</b> In a pharmacokinetic study conducted in 14 healthy volunteers, the maximum serum concentration and AUC of sirolimus (20 mg single oral dose given on day 9) decreased 71% and 82%, respectively, when co-administered with the strong CYP3A4 inducer rifampin (600 mg daily for 14 days).<sup>1,2</sup> A pharmacokinetic evaluation in a liver transplant recipient receiving sirolimus and phenytoin found that the sirolimus AUC, minimum serum concentration, and half-life increased 1.7-fold, 3.8-fold, and 2.2-fold, respectively, 10 days after phenytoin discontinuation.<sup>3</sup> Case reports describe transplant recipients treated with sirolimus who required 4-fold to 6-fold increases in their sirolimus dose after initiation of rifampin (when given as part of a multidrug regimen to treat tuberculosis)<sup>4</sup> or phenytoin.<sup>5</sup> Another report describes a renal transplant recipient in whom therapeutic sirolimus levels were not achieved while receiving concurrent phenytoin, despite a 10-fold sirolimus dose increase.<sup>6</sup><br> <br>Sirolimus prescribing information states that concomitant use of sirolimus with strong CYP3A4 inducers should be avoided if possible and alternative agents with less potential for interaction should be considered.<sup>1</sup> Although the sirolimus prescribing information lists rifabutin as an example of a strong CYP3A4 inducer, the majority of clinical data suggests it is a weak CYP3A4 inducer.<sup>7</sup> <br> <br>The mechanism of this interaction is likely induction of CYP3A4 and P-glycoprotein, an enzyme and transporter involved in sirolimus metabolism and disposition, by strong CYP3A4 inducers.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Rapamune (sirolimus) [prescribing information]. Philadelphia, PA: Wyeth Pharmaceuticals, Inc, November 2015.</p>\n<p>2. Tortorici MA, Matschke K, Korth-Bradley JM, DiLea C, Lasseter KC. The effect of rifampin on the pharmacokinetics of sirolimus in healthy volunteers. <i>Clin Pharmacol Drug Dev</i>. 2014;3(1):51-56. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=27128230\">[PubMed 27128230]</a></p>\n<p>3. Fridell JA, Jain AK, Patel K, et al. Phenytoin decreases the blood concentrations of sirolimus in a liver transplant recipient: a case report. <i>Ther Drug Monit</i>. 2003;25(1):117-119. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12548156\">[PubMed 12548156]</a></p>\n<p>4. Ngo BT, Pascoe M, Khan D. Drug interaction between rifampicin and sirolimus in transplant patients. <i>Saudi J Kidney Dis Transpl</i>. 2011;22(1):112-115. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21196624\">[PubMed 21196624]</a></p>\n<p>5. Bates D, Burak KW, Coffin CS, Ying T, Enns EM. Phenytoin-induced reduction in sirolimus levels. <i>Can J Hosp Pharm</i>. 2011;64(4):271-274. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22479070\">[PubMed 22479070]</a></p>\n<p>6. Hodges CB, Maxwell H, Beattie TJ, Murphy AV, Jindal RM. Use of rapamycin in a transplant patient who developed cyclosporin neurotoxicity. <i>Pediatr Nephrol</i>. 2001;16(10):777-778. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11605780\">[PubMed 11605780]</a></p>\n<p>7. Mycobutin (rifabutin) [prescribing information]. New York, NY: Pfizer Inc; May 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11860":"<p><b>Title</b> RomiDEPsin / Rifabutin</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Rifabutin may decrease the serum concentration of RomiDEPsin. <b>Severity</b> Minor <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> Though specific data are currently lacking, romidepsin prescribing information recommends avoiding concurrent use of a strong CYP3A4 inducer with romidepsin whenever possible due to the risk for decreased romidepsin concentrations and diminished clinical effectiveness.<sup>1</sup> Romidepsin is metabolized by CYP3A4, so strong CYP3A4 inducers would be expected to significantly increase romidepsin metabolism. Although romidepsin prescribing information lists rifabutin as an example of a strong CYP3A4 inducer, the clinical data suggest it is weak CYP3A4 inducer.<sup>2</sup><br><br>In a clinical study summarized in romidepsin U.S. prescribing information, coadministration with rifampin actually increased the romidepsin (14 mg/m2 infused over 4 hours) maximum concentration and AUC 60% and 80%, respectively, in patients with advanced cancer.<sup>1</sup> This may have resulted from rifampin inhibition of hepatic uptake of romidepsin, rather than the expected induction of romidepsin metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Istodax (romidepsin) [prescribing information]. Summit, NJ: Celgene Corporation; July 2016.</p>\n<p>2. Mycobutin (rifabutin) [prescribing information]. New York, NY: Pfizer Inc; May 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11861":"<p><b>Title</b> RomiDEPsin / Rifapentine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Rifapentine may decrease the serum concentration of RomiDEPsin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for reduced romidepsin effectiveness if combined with rifapentine.</p> \n<p><b>Discussion</b> Though specific data are currently lacking, romidepsin prescribing information recommends avoiding concurrent use of a strong CYP3A4 inducer with romidepsin whenever possible due to the risk for decreased romidepsin concentrations and diminished clinical effectiveness.<sup>1</sup> Romidepsin is metabolized by CYP3A4, so strong CYP3A4 inducers would be expected to significantly increase romidepsin metabolism. Although romidepsin prescribing information lists rifapentine as an example of a strong CYP3A4 inducer, the clinical data suggest it is moderate CYP3A4 inducer.<sup>2</sup><br><br>In a clinical study summarized in romidepsin U.S. prescribing information, coadministration with rifampin actually increased the romidepsin (14 mg/m2 infused over 4 hours) maximum concentration and AUC 60% and 80%, respectively, in patients with advanced cancer.<sup>1</sup> This may have resulted from rifampin inhibition of hepatic uptake of romidepsin, rather than the expected induction of romidepsin metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Istodax (romidepsin) [prescribing information]. Summit, NJ: Celgene Corporation; July 2016.</p>\n<p>2. Priftin (rifapentine) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis US LLC; November 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11862":"<p><b>Title</b> Enzalutamide / Rifapentine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Rifapentine may decrease the serum concentration of Enzalutamide. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for reduced enzalutamide efficacy if combined with rifapentine. Consider increasing the enzalutamide dose from 160 mg to 240 mg daily.</p> \n<p><b>Discussion</b> According to the enzalutamide prescribing information, the composite AUC of enzalutamide and N-desmethyl enzalutamide was an average of 37% lower with concurrent use of the strong CYP3A4 inducer rifampin (600 mg daily).<sup>1</sup> The prescribing information recommends that use of strong CYP3A4 inducers with enzalutamide should be avoided, and that if this combination cannot be avoided, the dose of enzalutamide should be increased from 160 mg to 240 mg daily. Although enzalutamide prescribing information lists rifapentine as a strong CYP3A4 inducer, the clinical data suggest it is a moderate CYP3A4 inducer.<sup>2</sup> <br><br>The mechanism of this interaction is most likely an increase in enzalutamide metabolism via induction of CYP3A4, which is one of the enzymes responsible for enzalutamide metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Xtandi (enzalutamide) [prescribing information]. Northbrook, IL: Astellas Pharma US Inc; July 2017.</p>\n<p>2. Priftin (rifapentine) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis US LLC; November 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11863":"<p><b>Title</b> Enzalutamide / Rifabutin</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Rifabutin may decrease the serum concentration of Enzalutamide. <b>Severity</b> Minor <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> According to the enzalutamide prescribing information, the composite AUC of enzalutamide and N-desmethyl enzalutamide was an average of 37% lower with concurrent use of the strong CYP3A4 inducer rifampin (600 mg daily).<sup>1</sup> The prescribing information recommends that use of strong CYP3A4 inducers with enzalutamide should be avoided, and that if this combination cannot be avoided, the dose of enzalutamide should be increased from 160 mg to 240 mg daily. Although enzalutamide prescribing information lists rifabutin as a strong CYP3A4 inducer, the clinical data suggest it is a weak CYP3A4 inducer.<sup>2</sup> <br><br>The mechanism of this interaction is most likely an increase in enzalutamide metabolism via induction of CYP3A4, which is one of the enzymes responsible for enzalutamide metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Xtandi (enzalutamide) [prescribing information]. Northbrook, IL: Astellas Pharma US Inc; July 2017.</p>\n<p>2. Mycobutin (rifabutin) [prescribing information]. New York, NY: Pfizer Inc; May 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11864":"<p><b>Title</b> Abiraterone Acetate / Rifabutin</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Rifabutin may decrease the serum concentration of Abiraterone Acetate. <b>Severity</b> Minor <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> In a clinical study summarized in abiraterone acetate US prescribing information, coadministration of the strong CYP3A4 inducer rifampin (600 mg daily for 6 days) decreased the AUC of abiraterone 55% following a single 1 g dose of abiraterone acetate.<sup>1</sup> <br><br>The abiraterone acetate prescribing information states that concomitant use of abiraterone acetate with strong CYP3A4 inducer should be avoided if possible.<sup>1</sup> If such a combination cannot be avoided, increase abiraterone acetate dosing frequency from once daily to twice daily during concomitant use.<sup>1</sup> Although the abiraterone acetate prescribing information lists rifabutin as an example of a strong CYP3A4 inducer, the clinical data suggest it is only a weak CYP3A4 inducer.<sup>2</sup><br><br>The suspected primary mechanism of this interaction is rifampin induction of CYP3A4 mediated abiraterone metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Zytiga (abiraterone acetate) [prescribing information]. Horsham, PA: Janssen Biotech Inc; May 2016.</p>\n<p>2. Mycobutin (rifabutin) [prescribing information]. New York, NY: Pfizer Inc; May 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11865":"<p><b>Title</b> Abiraterone Acetate / Rifapentine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Rifapentine may decrease the serum concentration of Abiraterone Acetate. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for decreased abiraterone acetate efficacy if combined with rifapentine. Consider increasing the dosing frequency from once daily to twice daily during concomitant use.</p> \n<p><b>Discussion</b> In a clinical study summarized in abiraterone acetate US prescribing information, coadministration of the strong CYP3A4 inducer rifampin (600 mg daily for 6 days) decreased the AUC of abiraterone 55% following a single 1 g dose of abiraterone acetate.<sup>1</sup> <br><br>The abiraterone acetate prescribing information states that concomitant use of abiraterone acetate with strong CYP3A4 inducer should be avoided if possible.<sup>1</sup> If such a combination cannot be avoided, increase abiraterone acetate dosing frequency from once daily to twice daily during concomitant use.<sup>1</sup> Although the abiraterone acetate prescribing information lists rifapentine as an example of a strong CYP3A4 inducer, the clinical data suggest it is only a moderate CYP3A4 inducer.<sup>2</sup><br><br>The suspected primary mechanism of this interaction is rifampin induction of CYP3A4 mediated abiraterone metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Zytiga (abiraterone acetate) [prescribing information]. Horsham, PA: Janssen Biotech Inc; May 2016.</p>\n<p>2. Priftin (rifapentine) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis US LLC; November 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11866":"<p><b>Title</b> Simeprevir / Rifabutin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Rifabutin may decrease the serum concentration of Simeprevir. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for reduced simeprevir effectiveness if combined with simeprevir.</p> \n<p><b>Discussion</b> According to simeprevir US prescribing information, the simeprevir minimum serum concentration (Cmin) and AUC were an average of 91% and 71% lower, respectively, with concurrent use of the moderate CYP3A4 inducer efavirenz in a study of subjects who received simeprevir (150 mg daily) with efavirenz (600 mg daily) for 14 days.<sup>1</sup> In another study, the strong CYP3A4 inducer rifampin (600 mg daily) decreased the simeprevir (200 mg daily) AUC and Cmin 48% and 92%, respectively.<sup>1</sup><br><br>The suspected mechanism for this interaction is induction of the CYP3A4 enzyme primarily responsible for simeprevir metabolism, resulting in reduced simeprevir concentrations.<br><br>Based on expectations that all moderate or strong CYP3A4 inducers may similarly reduce simeprevir concentrations, possibly interfering with its clinical effectiveness, the simeprevir prescribing information states that concurrent use of simeprevir with moderate or strong CYP3A4 inducers is not recommended.<sup>1</sup> Although rifabutin is listed as drug that will also likely decrease simeprevir concentrations, it should be noted that the majority of clinical data suggest that rifabutin is only a weak CYP3A4 inducer and would likely have a small effect on simeprevir exposure.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Olysio (simeprevir) [prescribing information]. Titusville, NJ: Janssen Therapeutics; November 2017.</p>\n<p>2. Mycobutin (rifabutin) [prescribing information]. New York, NY: Pfizer Inc; May 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11867":"<p><b>Title</b> VinCRIStine (Liposomal) / Rifapentine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Rifapentine may decrease the serum concentration of VinCRIStine (Liposomal). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for decreased vincristine effectiveness if combined with rifapentine. Consider avoiding this combination if possible.</p> \n<p><b>Discussion</b> In a clinical study of 15 adults with brain tumors treated with non-liposomal vincristine (2 mg intravenously), procarbazine, and lomustine, vincristine AUC was 43% lower in 9 patients who were receiving phenytoin or carbamazepine compared to patients receiving neither drug.<sup>2</sup> The likely primary mechanism of this interaction is induction of hepatic metabolism of vincristine (via CYP3A4) by carbamazepine or phenytoin. <br><br>Due to the potential for similar effects with liposomal vincristine, US prescribing information for liposomal vincristine specifically states that concomitant treatment with any strong CYP3A inducer should be avoided.<sup>2</sup> Although the prescribing information lists rifabutin as an example of a strong CYP3A4 inducer, the clinical data suggest it is a moderate CYP3A4 inducer.<sup>3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Villikka K, Kivisto KT, Maenpaa H, Joensuu H, Neuvonen PJ. Cytochrome P450-inducing antiepileptics increase the clearance of vincristine in patients with brain tumors. <i>Clin Pharmacol Ther</i>. 1999;66(6):589-593. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10613614\">[PubMed 10613614]</a></p>\n<p>2. Marqibo (vincristine, liposomal) [prescribing information]. South San Francisco, CA: Talon Therapeutics Inc; August 2012.</p>\n<p>3. Priftin (rifapentine) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis US LLC; November 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11868":"<p><b>Title</b> VinCRIStine (Liposomal) / Rifabutin</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Rifabutin may decrease the serum concentration of VinCRIStine (Liposomal). <b>Severity</b> Minor <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> In a clinical study of 15 adults with brain tumors treated with non-liposomal vincristine (2 mg intravenously), procarbazine, and lomustine, vincristine AUC was 43% lower in 9 patients who were receiving phenytoin or carbamazepine compared to patients receiving neither drug.<sup>2</sup> The likely primary mechanism of this interaction is induction of hepatic metabolism of vincristine (via CYP3A4) by carbamazepine or phenytoin. <br><br>Due to the potential for similar effects with liposomal vincristine, US prescribing information for liposomal vincristine specifically states that concomitant treatment with any strong CYP3A inducer should be avoided.<sup>2</sup> Although the prescribing information lists rifabutin as an example of a strong CYP3A4 inducer, the clinical data suggest it is only a weak CYP3A4 inducer.<sup>3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Villikka K, Kivisto KT, Maenpaa H, Joensuu H, Neuvonen PJ. Cytochrome P450-inducing antiepileptics increase the clearance of vincristine in patients with brain tumors. <i>Clin Pharmacol Ther</i>. 1999;66(6):589-593. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10613614\">[PubMed 10613614]</a></p>\n<p>2. Marqibo (vincristine, liposomal) [prescribing information]. South San Francisco, CA: Talon Therapeutics Inc; August 2012.</p>\n<p>3. Mycobutin (rifabutin) [prescribing information]. New York, NY: Pfizer Inc; May 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11869":"<p><b>Title</b> Nilotinib / Rifabutin</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Rifabutin may decrease the serum concentration of Nilotinib. <b>Severity</b> Minor <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> Coadministration of nilotinib with the strong CYP3A4 inducer rifampin (600mg daily x 12 days) was associated with a decrease in nilotinib AUC by approximately 80% in a study of healthy subjects.<sup>1</sup> <br><br>Due to concerns of decreased effectiveness, nilotinib prescribing information recommends avoiding concurrent use of nilotinib with strong CYP3A4 inducers.<sup>2</sup> Although the nilotinib prescribing information lists rifabutin as a strong CYP3A4 inducer, clinical data suggests it is only a weak CYP3A4 inducer.<sup>3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Tanaka C, Yin OQ, Smith T, et al. Effects of rifampin and ketoconazole on the pharmacokinetics of nilotinib in healthy participants. <i>J Clin Pharmacol</i>. 2011;51(1):75-83. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20702754\">[PubMed 20702754]</a></p>\n<p>2. Tasigna (nilotinib) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; December 2017.</p>\n<p>3. Mycobutin (rifabutin) [prescribing information]. New York, NY: Pfizer Inc; May 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11870":"<p><b>Title</b> Nilotinib / Rifapentine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Rifapentine may decrease the serum concentration of Nilotinib. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for decreased nilotinib effectiveness if combined with rifapentine.</p> \n<p><b>Discussion</b> Coadministration of nilotinib with the strong CYP3A4 inducer rifampin (600mg daily x 12 days) was associated with a decrease in nilotinib AUC by approximately 80% in a study of healthy subjects.<sup>1</sup> <br><br>Due to concerns of decreased effectiveness, nilotinib prescribing information recommends avoiding concurrent use of nilotinib with strong CYP3A4 inducers.<sup>2</sup> Although the nilotinib prescribing information lists rifapentine as a strong CYP3A4 inducer, clinical data suggests rifapentine is a moderate CYP3A4 inducer.<sup>3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Tanaka C, Yin OQ, Smith T, et al. Effects of rifampin and ketoconazole on the pharmacokinetics of nilotinib in healthy participants. <i>J Clin Pharmacol</i>. 2011;51(1):75-83. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20702754\">[PubMed 20702754]</a></p>\n<p>2. Tasigna (nilotinib) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; December 2017.</p>\n<p>3. Priftin (rifapentine) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis US LLC; November 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11871":"<p><b>Title</b> Irinotecan Products / Rifabutin</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Rifabutin may decrease serum concentrations of the active metabolite(s) of Irinotecan Products. Specifically, serum concentrations of SN-38 may be reduced. Rifabutin may decrease the serum concentration of Irinotecan Products. <b>Severity</b> Minor <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> No action required.</p>\n<div>\n <p><b>Irinotecan Products Interacting Members</b> Irinotecan (Conventional), Irinotecan (Liposomal)</p>\n</div> \n<p><b>Discussion</b> In a study aiming to minimize dose-limiting toxicities of irinotecan while permitting the use of larger doses, the addition of phenobarbital (90mg) to patients (N=39) who were receiving irinotecan (72-144mg/m<sup>2</sup>) and cyclosporine (5mg/kg -- used to inhibit the transport of the active irinotecan metabolite SN-38 into the biliary tract) was associated with a mean 27% decrease in irinotecan AUC, a mean 75% decrease in SN-38 AUC, and a mean 50% decrease in SN-38-glucuronide AUC.<sup>1</sup> Irinotecan clearance was increased by an average of 50% after addition of phenobarbital. In vitro and animal studies with phenobarbital and irinotecan similarly show decreased irinotecan and SN-38 concentrations with this combination, via an apparent induction of both irinotecan and SN-38 metabolism.<sup>2,3</sup><br><br>Enzyme-inducing anticonvulsant therapy (primarily phenytoin) was also associated with reduced SN-38 concentrations, increased irinotecan clearance, and a nearly 2-fold increase in the SN-38 glucuronide-to-SN-38 ratio in a study of pediatric brain cancer patients.<sup>4</sup> Ten of the 31 patients studied were in the enzyme-inducing anticonvulsant group, but only 4 received the enzyme-inducing agents throughout the study (5 discontinued 2-3 days prior to irinotecan, and 1 discontinued after study day 1). Observation of these pharmacokinetic changes despite early cessation in several patients emphasizes the magnitude and persistence of the enzyme induction. Similarly, other case reports, clinical interaction studies, and in vitro studies with other enzyme-inducing anticonvulsants (ie phenytoin, carbamazepine) have further demonstrated significant induction of irinotecan and SN-38 metabolism, resulting in possibly substantial reductions in exposure.<sup>5,6,7,8</sup><br><br>The suspected mechanism of these interactions is induction of the enzymes (CYP3A4, possibly UGT1A1) mediating metabolism of irinotecan and its metabolites. Irinotecan US prescribing information states that it should not be used in combination with strong CYP3A4 inducing agents unless no therapeutic alternatives exist, and that consideration should be given to substituting a non-inducing alternative drug at least 2 weeks prior to irinotecan initiation.<sup>9,10</sup> Although irinotecan prescribing information lists rifabutin as an example of a strong CYP3A4 inducer, clinical data suggest it is only a weak CYP3A4 inducer.<sup>11</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Innocenti F, Undevia SD, Ramirez J, et al. A phase I trial of pharmacologic modulation of irinotecan with cyclosporine and phenobarbital. <i>Clin Pharmacol Ther</i>. 2004;76(5):490-502. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15536463\">[PubMed 15536463]</a></p>\n<p>2. Gupta E, Wang X, Ramirez J, Ratain MJ. Modulation of glucuronidation of SN-38, the active metabolite of irinotecan, by valproic acid and phenobarbital. <i>Cancer Chemother Pharmacol</i>. 1997;39(5):440-444. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9054958\">[PubMed 9054958]</a></p>\n<p>3. Mirkov S, Komoroski BJ, Ramirez J, et al. Effects of green tea compounds on irinotecan metabolism. <i>Drug Metab Dispos</i>. 2007;35(2):228-233. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17108060\">[PubMed 17108060]</a></p>\n<p>4. Crews KR, Stewart CF, Jones-Wallace D, et al. Altered irinotecan pharmacokinetics in pediatric high-grade glioma patients receiving enzyme-inducing anticonvulsant therapy. <i>Clin Cancer Res</i>. 2002;8(7):2202-2209. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12114421\">[PubMed 12114421]</a></p>\n<p>5. Chamberlain MC. Salvage chemotherapy with CPT-11 for recurrent glioblastoma multiforme. <i>J Neurooncol</i>. 2002;56(2):183-188. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11995820\">[PubMed 11995820]</a></p>\n<p>6. Kuhn JG. Influence of anticonvulsants on the metabolism and elimination of irinotecan. A North American Brain Tumor Consortium preliminary report. <i>Oncology (Williston Park)</i>. 2002;16(8 suppl 7):33-40. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12199631\">[PubMed 12199631]</a></p>\n<p>7. Mathijssen RH, Sparreboom A, Dumez H, van Oosterom AT, de Bruijn EA. Altered irinotecan metabolism in a patient receiving phenytoin. <i>Anticancer Drugs</i>. 2002;13(2):139-140. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11901305\">[PubMed 11901305]</a></p>\n<p>8. Murry DJ, Cherrick I, Salama V, et al. Influence of phenytoin on the disposition of irinotecan: a case report. <i>J Pediatr Hematol Oncol</i>. 2002;24(2):130-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11990699\">[PubMed 11990699]</a></p>\n<p>9. Camptosar (irinotecan) [prescribing information]. New York, NY: Pharmacia &amp; Upjohn Co; December 2014.</p>\n<p>10. Onivyde (irinotecan liposomal) [prescribing information]. Cambridge, MA: Merrimack Pharmaceuticals Inc; October 2015.</p>\n<p>11. Mycobutin (rifabutin) [prescribing information]. New York, NY: Pfizer Inc; May 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11872":"<p><b>Title</b> Irinotecan Products / Rifapentine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Rifapentine may decrease serum concentrations of the active metabolite(s) of Irinotecan Products. Specifically, serum concentrations of SN-38 may be reduced. Rifapentine may decrease the serum concentration of Irinotecan Products. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for reduced irinotecan concentrations and effects if combined with rifapentine. Consider alternatives to this combination.</p>\n<div>\n <p><b>Irinotecan Products Interacting Members</b> Irinotecan (Conventional), Irinotecan (Liposomal)</p>\n</div> \n<p><b>Discussion</b> In a study aiming to minimize dose-limiting toxicities of irinotecan while permitting the use of larger doses, the addition of phenobarbital (90mg) to patients (N=39) who were receiving irinotecan (72-144mg/m<sup>2</sup>) and cyclosporine (5mg/kg -- used to inhibit the transport of the active irinotecan metabolite SN-38 into the biliary tract) was associated with a mean 27% decrease in irinotecan AUC, a mean 75% decrease in SN-38 AUC, and a mean 50% decrease in SN-38-glucuronide AUC.<sup>1</sup> Irinotecan clearance was increased by an average of 50% after addition of phenobarbital. In vitro and animal studies with phenobarbital and irinotecan similarly show decreased irinotecan and SN-38 concentrations with this combination, via an apparent induction of both irinotecan and SN-38 metabolism.<sup>2,3</sup><br><br>Enzyme-inducing anticonvulsant therapy (primarily phenytoin) was also associated with reduced SN-38 concentrations, increased irinotecan clearance, and a nearly 2-fold increase in the SN-38 glucuronide-to-SN-38 ratio in a study of pediatric brain cancer patients.<sup>4</sup> Ten of the 31 patients studied were in the enzyme-inducing anticonvulsant group, but only 4 received the enzyme-inducing agents throughout the study (5 discontinued 2-3 days prior to irinotecan, and 1 discontinued after study day 1). Observation of these pharmacokinetic changes despite early cessation in several patients emphasizes the magnitude and persistence of the enzyme induction. Similarly, other case reports, clinical interaction studies, and in vitro studies with other enzyme-inducing anticonvulsants (ie phenytoin, carbamazepine) have further demonstrated significant induction of irinotecan and SN-38 metabolism, resulting in possibly substantial reductions in exposure.<sup>5,6,7,8</sup><br><br>The suspected mechanism of these interactions is induction of the enzymes (CYP3A4, possibly UGT1A1) mediating metabolism of irinotecan and its metabolites. Irinotecan US prescribing information states that it should not be used in combination with strong CYP3A4 inducing agents unless no therapeutic alternatives exist, and that consideration should be given to substituting a non-inducing alternative drug at least 2 weeks prior to irinotecan initiation.<sup>9,10</sup> Although irinotecan prescribing information lists rifapentine as an example of a strong CYP3A4 inducer, clinical data suggest it is a moderate CYP3A4 inducer.<sup>11</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Innocenti F, Undevia SD, Ramirez J, et al. A phase I trial of pharmacologic modulation of irinotecan with cyclosporine and phenobarbital. <i>Clin Pharmacol Ther</i>. 2004;76(5):490-502. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15536463\">[PubMed 15536463]</a></p>\n<p>2. Gupta E, Wang X, Ramirez J, Ratain MJ. Modulation of glucuronidation of SN-38, the active metabolite of irinotecan, by valproic acid and phenobarbital. <i>Cancer Chemother Pharmacol</i>. 1997;39(5):440-444. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9054958\">[PubMed 9054958]</a></p>\n<p>3. Mirkov S, Komoroski BJ, Ramirez J, et al. Effects of green tea compounds on irinotecan metabolism. <i>Drug Metab Dispos</i>. 2007;35(2):228-233. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17108060\">[PubMed 17108060]</a></p>\n<p>4. Crews KR, Stewart CF, Jones-Wallace D, et al. Altered irinotecan pharmacokinetics in pediatric high-grade glioma patients receiving enzyme-inducing anticonvulsant therapy. <i>Clin Cancer Res</i>. 2002;8(7):2202-2209. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12114421\">[PubMed 12114421]</a></p>\n<p>5. Chamberlain MC. Salvage chemotherapy with CPT-11 for recurrent glioblastoma multiforme. <i>J Neurooncol</i>. 2002;56(2):183-188. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11995820\">[PubMed 11995820]</a></p>\n<p>6. Kuhn JG. Influence of anticonvulsants on the metabolism and elimination of irinotecan. A North American Brain Tumor Consortium preliminary report. <i>Oncology (Williston Park)</i>. 2002;16(8 suppl 7):33-40. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12199631\">[PubMed 12199631]</a></p>\n<p>7. Mathijssen RH, Sparreboom A, Dumez H, van Oosterom AT, de Bruijn EA. Altered irinotecan metabolism in a patient receiving phenytoin. <i>Anticancer Drugs</i>. 2002;13(2):139-140. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11901305\">[PubMed 11901305]</a></p>\n<p>8. Murry DJ, Cherrick I, Salama V, et al. Influence of phenytoin on the disposition of irinotecan: a case report. <i>J Pediatr Hematol Oncol</i>. 2002;24(2):130-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11990699\">[PubMed 11990699]</a></p>\n<p>9. Camptosar (irinotecan) [prescribing information]. New York, NY: Pharmacia &amp; Upjohn Co; December 2014.</p>\n<p>10. Onivyde (irinotecan liposomal) [prescribing information]. Cambridge, MA: Merrimack Pharmaceuticals Inc; October 2015.</p>\n<p>11. Priftin (rifapentine) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis US LLC; November 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11873":"<p><b>Title</b> Cabozantinib / Rifapentine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Rifapentine may decrease the serum concentration of Cabozantinib. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for decreased cabozantinib efficacy if combined with rifapentine.</p> \n<p><b>Discussion</b> The AUC of cabozantinib was reduced an average of 77% when given with the strong CYP3A4 inducer rifampin in a study of healthy volunteers who were given a single dose of cabozantinib together with rifampin (600 mg/day for 31 days).<sup>1,2</sup> <br><br>Cabozantinib prescribing information states that concomitant use of strong CYP3A4 inducers with cabozantinib should be avoided if possible. If combined, cabozantinib dose adjustments are recommended and vary based on the cabozantinib product used and the indication for use. Although cabozantinib prescribing information lists rifapentine as an example of a strong CYP3A4 inducer, clinical data suggest it is only a moderate CYP3A4 indcuer.<sup>3</sup> <br><br>The likely mechanism of this interaction is increased CYP3A4-mediated metabolism of cabozantinib by rifampin.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Cometriq (cabozantinib) capsules [prescribing information]. South San Francisco, CA: Exelixis Inc; November 2012.</p>\n<p>2. Cabometyx (cabozantinib) tablets [prescribing information]. South San Francisco, CA: Exelixis Inc; April 2016.</p>\n<p>3. Priftin (rifapentine) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis US LLC; November 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11874":"<p><b>Title</b> Cabozantinib / Rifabutin</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Rifabutin may decrease the serum concentration of Cabozantinib. <b>Severity</b> Minor <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> The AUC of cabozantinib was reduced an average of 77% when given with the strong CYP3A4 inducer rifampin in a study of healthy volunteers who were given a single dose of cabozantinib together with rifampin (600 mg/day for 31 days).<sup>1,2</sup> <br><br>Cabozantinib prescribing information states that concomitant use of strong CYP3A4 inducers with cabozantinib should be avoided if possible. If combined, cabozantinib dose adjustments are recommended and vary based on the cabozantinib product used and the indication for use. Although cabozantinib prescribing information lists rifabutin as an example of a strong CYP3A4 inducer, clinical data suggest it is only a weak CYP3A4 indcuer.<sup>3</sup> <br><br>The likely mechanism of this interaction is increased CYP3A4-mediated metabolism of cabozantinib by rifampin.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Cometriq (cabozantinib) capsules [prescribing information]. South San Francisco, CA: Exelixis Inc; November 2012.</p>\n<p>2. Cabometyx (cabozantinib) tablets [prescribing information]. South San Francisco, CA: Exelixis Inc; April 2016.</p>\n<p>3. Mycobutin (rifabutin) [prescribing information]. New York, NY: Pfizer Inc; May 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11875":"<p><b>Title</b> Everolimus / Rifapentine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Rifapentine may decrease the serum concentration of Everolimus. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for reduced everolimus serum concentrations and efficacy if combined with rifapentine.</p> \n<p><b>Discussion</b> Everolimus AUC and maximum plasma concentration were decreased by 63% and 58%, respectively, when everolimus (4 mg single dose) was administered to healthy subjects (n=16) who had been receiving the strong CYP3A4 inducer rifampin (600 mg daily) for 8 days.<sup>1</sup> Everolimus half-life decreased by 25%, and the apparent clearance increased 172%.<br><br>As a result of the potential for a significant interaction, everolimus prescribing information recommends avoiding concurrent use of rifampin or other strong CYP3A4 inducers.<sup>2</sup> Although everolimus prescribing information lists rifapentine as an example of a strong CYP3A4 inducer, clinical data suggest it is a moderate CYP3A4 inducer.<sup>3</sup><br><br>The mechanism of this potential interaction is likely induction of CYP3A4 and/or P-glycoprotein, an enzyme and transporter responsible for everolimus metabolism and distribution.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Kovarik JM, Hartmann S, Figueiredo J, Rouilly M, Port A, Rordorf C. Effect of rifampin on apparent clearance of everolimus. <i>Ann Pharmacother</i>. 2002;36(6):981-985. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12022896\">[PubMed 12022896]</a></p>\n<p>2. Afinitor (everolimus) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; January 2016.</p>\n<p>3. Priftin (rifapentine) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis US LLC; November 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11876":"<p><b>Title</b> Everolimus / Rifabutin</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Rifabutin may decrease the serum concentration of Everolimus. <b>Severity</b> Minor <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> Everolimus AUC and maximum plasma concentration were decreased 63% and 58%, respectively, when everolimus (4 mg single dose) was administered to healthy subjects (n=16) who had been receiving the strong CYP3A4 inducer rifampin (600 mg daily) for 8 days.<sup>1</sup> Everolimus half-life decreased 25% and the apparent clearance increased 172%.<br><br>As a result of the potential for a significant interaction, everolimus prescribing information recommends avoiding concurrent use of rifampin or other strong CYP3A4 inducers.<sup>2</sup> Although everolimus prescribing information lists rifabutin as an example of a strong CYP3A4 inducer, clinical data suggest it is only a weak CYP3A4 inducer.<sup>3</sup> Additionally, one case report describes a patient who experienced subtherapeutic everolimus concentrations while taking rifampin, but was able to maintain adequate everolimus levels after changing rifampin to rifabutin.<sup>4</sup><br><br>The mechanism of this potential interaction is likely induction of CYP3A4 and/or P-glycoprotein, an enzyme and transporter responsible for everolimus metabolism and distribution.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Kovarik JM, Hartmann S, Figueiredo J, Rouilly M, Port A, Rordorf C. Effect of rifampin on apparent clearance of everolimus. <i>Ann Pharmacother</i>. 2002;36(6):981-985. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12022896\">[PubMed 12022896]</a></p>\n<p>2. Afinitor (everolimus) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; January 2016.</p>\n<p>3. Mycobutin (rifabutin) [prescribing information]. New York, NY: Pfizer Inc; May 2015.</p>\n<p>4. Lefeuvre S, Rebaudet S, Billaud EM, Wyplosz B. Management of rifamycins-everolimus drug-drug interactions in a liver-transplant patient with pulmonary tuberculosis. <i>Transpl Int</i>. 2012;25(11):e120-e123. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22994607\">[PubMed 22994607]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11877":"<p><b>Title</b> Piperaquine / CYP3A4 Inhibitors (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Strong) may enhance the QTc-prolonging effect of Piperaquine. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Piperaquine. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid the concomitant use of piperaquine and strong CYP3A4 inhibitors when possible. If this combination cannot be avoided, frequent ECG monitoring is recommended due to the increased risk for QTc prolongation associated with increased piperaquine exposure.</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Strong) Interacting Members</b> Atazanavir, Boceprevir, Clarithromycin, Cobicistat, Darunavir, Idelalisib, Indinavir, Itraconazole, Ketoconazole (Systemic), Lopinavir, MiFEPRIStone, Nefazodone, Nelfinavir, Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, Posaconazole, Ritonavir, Saquinavir, Telaprevir, Telithromycin, Voriconazole</p>\n</div> \n<p><b>Discussion</b> A pharmacokinetic study referenced in the product labeling for Eurartesim (piperaquine/artenimol) states that the coadministration of a single dose of oral clarithromycin with a single dose of oral Eurartesim led to an increase (less than 2-fold) in piperaquine exposure in healthy adult subjects.<sup>1</sup> Increased piperaquine exposure may exacerbate the effect of piperaquine on QTc prolongation. <br><br>The product labeling for Eurartesim states that the coadministration of piperaquine with any strong CYP3A4 inhibitor should be avoided due to the increased risk for QTc prolongation associated with increased piperaquine exposure.<sup>1</sup> Frequent ECG monitoring is recommended if this combination cannot be avoided. <br><br>The primary mechanism of these potential interactions is inhibition of the CYP3A4-mediated metabolism of piperaquine by the coadministered drug.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Eurartesim (piperaquine and artenimol) tablets [UK EMA summary of product characteristics]. Milan, Italy: Alfasigma S.p.A; September 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11878":"<p><b>Title</b> Piperaquine / CYP3A4 Inducers (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> CYP3A4 Inducers (Strong) may decrease the serum concentration of Piperaquine. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid the concomitant use of piperaquine and strong CYP3A4 inducers due to the potential for decreased piperaquine plasma concentrations.</p>\n<div>\n <p><b>CYP3A4 Inducers (Strong) Interacting Members</b> Apalutamide, CarBAMazepine, Enzalutamide, Fosphenytoin, Lumacaftor, Mitotane, PHENobarbital, Phenytoin, Primidone, RifAMPin</p>\n</div> \n<p><b>Discussion</b> The product labeling for Eurartesim (piperaquine/artenimol) states that the coadministration of piperaquine with any strong CYP3A4 inducer should be avoided. Such combinations may result in reduced piperaquine plasma concentrations.<sup>1</sup> The primary mechanism of these potential interactions is induction of the CYP3A4-mediated metabolism of piperaquine by the coadministered drug.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Eurartesim (piperaquine and artenimol) tablets [UK EMA summary of product characteristics]. Milan, Italy: Alfasigma S.p.A; September 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11879":"<p><b>Title</b> Anticoagulants / Sulodexide</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Sulodexide may enhance the anticoagulant effect of Anticoagulants. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor clinical signs and symptoms of enhanced coagulation effects (eg, bleeding and bruising) and coagulation assay measurements, as appropriate, when coadministered with anticoagulants. Adjust therapy accordingly.</p>\n<div>\n <p><b>Anticoagulants Interacting Members</b> Acenocoumarol, Antithrombin, Apixaban, Argatroban, Bemiparin, Betrixaban, Bivalirudin, Dabigatran Etexilate, Dalteparin, Danaparoid, Desirudin, Edoxaban, Enoxaparin, Fondaparinux, Heparin, Nadroparin, Phenindione, Protein C Concentrate (Human), Rivaroxaban, Tinzaparin, Warfarin</p>\n</div> \n<p><b>Discussion</b> According to international prescribing information, sulodexide should be monitored when administered with other anticoagulants.<sup>1</sup> Sulodexide is comprised of 2 fractions, a fast moving heparin glycosaminoglycan and dermatan sulfate, which act on different parts of the coagulation cascade. It is thought to possess anticoagulation properties similar to low molecular weight heparins (LMWH) but due to its unique structure and effects on the coagulation cascade, sulodexide is considered to have less effects on coagulation tests and bleeding risk.<sup>2,3</sup> Although, there are no drug interaction studies in the literature, monitoring of appropriate coagulation assays and any clinical signs and symptoms (eg, bruising and bleeding) of enhanced anticoagulation are recommended.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Aju Vesseldue-F (sulodexide) tablet [KR prescribing information]. Available at http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=199700883. Accessed July 12, 2017.</p>\n<p>2. Lauver DA, Lucchesi BR. Sulodexide: a renewed interest in this glycosaminoglycan. <i>Cardiovasc Drug Rev</i>. 2006;24(3-4):214-226. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17214598\">[PubMed 17214598]</a> </p>\n<p>3. Coccheri S, Mannello F. Development and use of sulodexide in vascular disease: implications for treatment. <i>Drug Des Devel Ther</i>. 2014;8:49-65. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24391440\">[PubMed 24391440]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11880":"<p><b>Title</b> Piperaquine / St John's Wort</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> St John's Wort may decrease the serum concentration of Piperaquine. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid the concomitant use of piperaquine and St. John's Wort due to the potential for decreased piperaquine plasma concentrations.</p> \n<p><b>Discussion</b> The product labeling for Eurartesim (piperaquine/artenimol) states that the coadministration of piperaquine with St. John's Wort should be avoided. This combination may result in reduced piperaquine plasma concentrations.<sup>1</sup> The primary mechanism of this potential interaction is induction of the CYP3A4-mediated metabolism of piperaquine by St. John's Wort.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Eurartesim (piperaquine and artenimol) tablets [UK EMA summary of product characteristics]. Milan, Italy: Alfasigma S.p.A; September 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11881":"<p><b>Title</b> CYP3A4 Substrates (High risk with Inhibitors) / Piperaquine</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Piperaquine may increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). <b>Severity</b> Minor <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> No action required.</p>\n<div>\n <p><b>CYP3A4 Substrates (High risk with Inhibitors) Interacting Members</b> Abemaciclib, Acalabrutinib, Ado-Trastuzumab Emtansine, Alfentanil, Alfuzosin, Alitretinoin (Systemic), ALPRAZolam, Amiodarone, AmLODIPine, Aprepitant, ARIPiprazole, ARIPiprazole Lauroxil, Asunaprevir, Atazanavir, AtorvaSTATin, Avanafil, Axitinib, Barnidipine, Benidipine, Benzhydrocodone, Blonanserin, Bosutinib, Brexpiprazole, Brigatinib, Bromocriptine, Bromperidol, Budesonide (Systemic), Buprenorphine, BusPIRone, Cabazitaxel, Cabozantinib, Calcitriol (Systemic), CarBAMazepine, Cariprazine, Ceritinib, ChlordiazePOXIDE, Chloroquine, Cilnidipine, Cilostazol, Cinacalcet, Cisapride, Citalopram, Clarithromycin, ClonazePAM, Cobimetinib, Colchicine, Conivaptan, Copanlisib, Crizotinib, CycloSPORINE (Systemic), Cyproterone, Dabrafenib, Daclatasvir, Dapoxetine, Darifenacin, Darunavir, Dasatinib, Deflazacort, Dexamethasone (Systemic), DiazePAM, Digitoxin, Dihydroergotamine, DilTIAZem, Disopyramide, DOCEtaxel, Domperidone, Doxazosin, DOXOrubicin (Conventional), DOXOrubicin (Liposomal), Dronedarone, Dydrogesterone, Ebastine, Elbasvir, Eletriptan, Eliglustat, Eplerenone, Ergoloid Mesylates, Ergonovine, Ergotamine, Erlotinib, Erythromycin (Systemic), Escitalopram, Eszopiclone, Ethosuximide, Etizolam, Everolimus, Felbamate, Felodipine, FentaNYL, Fesoterodine, Flibanserin, Flurazepam, Fluticasone (Oral Inhalation), Fosaprepitant, Gefitinib, Grazoprevir, GuanFACINE, Halofantrine, Haloperidol, HYDROcodone, HYDROXYprogesterone Caproate, Ibrutinib, Irinotecan (Conventional), Irinotecan (Liposomal), Isavuconazonium Sulfate, Isosorbide Dinitrate, Isosorbide Mononitrate, Isradipine, Itraconazole, Ivabradine, Ivacaftor, Ixabepilone, Ketamine, Lacidipine, Lapatinib, Lercanidipine, Levomilnacipran, Lidocaine (Systemic), Lidocaine (Topical), Lomitapide, Lovastatin, Lurasidone, Macitentan, Manidipine, Maraviroc, Mefloquine, Methadone, Methylergonovine, Midazolam, Midostaurin, MiFEPRIStone, Mirodenafil, Mirtazapine, Naloxegol, Nefazodone, Neratinib, NiCARdipine, NIFEdipine, Nilotinib, Nilvadipine, NiMODipine, Nisoldipine, Nitrendipine, Olaparib, Olmutinib, Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, OxyCODONE, PACLitaxel (Conventional), PACLitaxel (Protein Bound), Palbociclib, Panobinostat, PAZOPanib, Pimavanserin, Pimozide, Piperaquine, Praziquantel, QUEtiapine, QuiNIDine, QuiNINE, Radotinib, Ranolazine, Reboxetine, Regorafenib, Ribociclib, Rupatadine, Ruxolitinib, Salmeterol, SAXagliptin, Sildenafil, Silodosin, Simeprevir, Simvastatin, Sirolimus, Solifenacin, Sonidegib, Stiripentol, SUFentanil, SUNItinib, Suvorexant, Tacrolimus (Systemic), Tadalafil, Tamoxifen, Tamsulosin, Telaprevir, Telithromycin, Temsirolimus, Teniposide, Tezacaftor, TiaGABine, Tofacitinib, Tolterodine, Tolvaptan, Trabectedin, TraZODone, Triazolam, Trimipramine, Udenafil, Valbenazine, Vardenafil, Vemurafenib, Venetoclax, Venlafaxine, Verapamil, VinBLAStine, VinCRIStine, VinCRIStine (Liposomal), Vinflunine, Vinorelbine, Zopiclone</p>\n</div> \n<p><b>Discussion</b> The Eurartesim (piperaquine/artenimol) prescribing information states that the coadministration of Eurartesim and oral midazolam (7.5 mg) led to an increase (2-fold or less) in midazolam and its metabolites' exposures in a study of healthy adult subjects.<sup>1</sup> There was no evidence of the inhibitory effect one week after the administration of the last Eurartesim dose.<sup>1</sup><br><br>Midazolam is considered a sensitive substrate for CYP3A4, often used in studies to detect CYP3A4 inhibition or induction. Piperaquine is an inhibitor of CYP3A,<sup>1</sup> making inhibition of the CYP3A-mediated metabolism (in the intestines and/or in the liver) of midazolam the likely mechanism for this observed interaction. Considering the magnitude of the interaction, this degree of inhibition is unlikely to be of clinical relevance for most CYP3A substrates.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Eurartesim (piperaquine and artenimol) tablets [UK EMA summary of product characteristics]. Milan, Italy: Alfasigma S.p.A; September 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11882":"<p><b>Title</b> Busulfan / Deferasirox</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Deferasirox may increase the serum concentration of Busulfan. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased busulfan concentrations and effects if combined with deferasirox. Decreased busulfan doses may be required during concomitant use.</p> \n<p><b>Discussion</b> One case report describes a 59-year-old female whose busulfan clearance during treatment with deferasirox was determined to be 1.74 mL/min/kg, a rate that was lower than expected.<sup>1</sup> After deferasirox discontinuation, her busulfan clearance increased 59%, to 2.76 mL/min/kg.<sup>1</sup> No other changes to her home medications occurred between busulfan clearance calculations.<sup>1</sup> Another case report describes an 8-year-old girl taking deferasirox whose busulfan clearance was only 1.44 mL/min/kg, a rate that was 2 to 3 standard deviations below the pediatric population average.<sup>2</sup> Fourteen days after deferasirox discontinuation, her busulfan clearance increased 82%, to 2.62 mL/min/kg.<sup>2</sup><br><br>The mechanism of this potential interaction has not been fully investigated. However, competition for glucuronidation enzymes or deferasirox-mediated inhibition of the oxidative metabolism of the busulfan conjugate metabolite may contribute.<sup>1,2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Sweiss K, Patel P, Rondelli D. Deferasirox increases BU blood concentrations. <i>Bone Marrow Transplant</i>. 2012;47(2):315-316. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21460865\">[PubMed 21460865]</a></p>\n<p>2. Kwiatkowski J, Duffner U, Abdel-Mageed A. Deferasirox decreases busulfan clearance. <i>Ann Pharmacother</i>. 2018;52(5):497-498. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=29319328\">[PubMed 29319328]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11889":"<p><b>Title</b> Vecuronium / MetroNIDAZOLE (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> MetroNIDAZOLE (Systemic) may enhance the neuromuscular-blocking effect of Vecuronium. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for signs and symptoms for enhanced neuromuscular blockade of vecuronium in patients who receive metronidazole. Patients receiving high doses of metronidazole may require dose adjustments for desired effects of vecuronium.</p> \n<p><b>Discussion</b> In patients undergoing abdominal surgery, metronidazole did not appear to potentiate vecuronium neuromuscular blockade at clinically relevant doses of metronidazole; however, with higher doses of the antibiotic, neuromuscular blockade was slightly enhanced with coadministration. When IV metronidazole (7.5 mg/kg or 15 mg/kg versus placebo) was administered with vercuronium (20 mcg/kg bolus, then 10 mcg/kg), the cessation of twitch tension was evaluated (part 1, n=20).<sup>1</sup> There was no difference in ED<sub>90</sub> between the 7.5 mg/kg metronidazole IV group and placebo (53 vs 56 mcg/kg) whereas a slight enhancement of neuromuscular blockade was observed in the 15 mg/kg metronidazole IV group (45 vs 56 mcg/kg). In part 2 of the same study (n=30), there was no increase in the time intervals of supplemental vercuronium injections (20 mcg/kg) in those patients receiving IV metronidazole 7.5 mg/kg versus placebo. The higher dose of metronidazole was not evaluated in part 2. <sup>1</sup><br><br>Although enhanced neuromuscular blockade was previously illustrated in cats, it could not be reproduced in a clinical setting.<sup>1,2</sup> There was, however, slightly enhanced neuromuscular blockade in the group receiving higher than usual metronidazole doses. Metronidazole prescribing information indicates effects of vecuronium may be potentiated; therefore, monitoring patients for enhanced neuromuscular blockade is recommended when vecuronium and metronidazole are coadministered.<sup>3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. d`Hollander A, Agoston S, Capouet V, Barvais L, Bomblet JP, Esselen M. Failure of metronidazole to alter a vecuronium neuromuscular blockade in humans. <i>Anesthesiology.</i> 1985; 63(1); 99-102. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2861766\">[PubMed 2861766]</a></p>\n<p>2. McIndewar IC, Marshall RJ. Interactions between the neuromuscular blocking drug Org NC 45 and some anaesthetic, analgesic and antimicrobial agents. <i>Br J Anaesth.</i> 1981;53(8):785-792. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6115660\">[PubMed 6115660]</a></p>\n<p>3. Viaflex Plus Container (metronidazole injection) [prescribing information]. Deerfield, IL: Baxter Healthcare Corporation; December 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11890":"<p><b>Title</b> Digoxin / Benidipine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Benidipine may increase the serum concentration of Digoxin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for increased digoxin levels/effects with benidipine initiation/dose increase. Conversely, monitor for decreased digoxin levels/effects with benidipine discontinuation/dose decrease.</p> \n<p><b>Discussion</b> The benidipine prescribing information cautions that increased digoxin serum concentrations may occur with the concomitant use of benidipine and digoxin.<sup>1</sup> There are no data to support this possible interaction. However, the benidipine product labeling advises that digoxin levels should be monitored during coadministration of benidipine and digoxin, and therapy should be discontinued should signs and symptoms of digoxin toxicity (eg, CNS disturbances, arrhythmia, nausea/vomiting) occur.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Codipin (benidipine hydrochloride) tablets [Korea KR prescribing information]. Available at: http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=199300958. Accessed October 26, 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11891":"<p><b>Title</b> Benidipine / Grapefruit Juice</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Grapefruit Juice may increase the serum concentration of Benidipine. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for excessive hemodynamic response (eg, reduced blood pressure and heart rate) to benidipine in patients who consume grapefruit juice.</p> \n<p><b>Discussion</b> In a controlled study of 6 subjects administered benidipine (4 mg) with or without grapefruit juice (200 mL), grapefruit juice consumption was associated with a mean 59% increase in the AUC of benidipine.<sup>1</sup> Accordingly, the prescribing information for benidipine cautions that the concomitant use of grapefruit juice and benidipine may result in an excessive hemodynamic response (eg, reduced blood pressure and heart rate) to benidipine.<sup>2</sup> <br><br>The mechanism of this interaction appears to be inhibition of CYP3A-mediated benidipine metabolism in the intestine, resulting in an increased bioavailability (and AUC).<sup>3</sup> Reviews of grapefruit juice interactions with benidipine and/or other calcium channel blockers have concluded that drugs with greater lipophilicity, lower bioavailability, and less protein binding tend to interact more strongly with grapefruit juice.<sup>1,3</sup> Based on these data (and consistent with available clinical data), oral benidipine would rank near the middle of the tested calcium channel blockers regarding its potential to interact strongly with grapefruit juice, with amlodipine and nifedipine among those least likely to interact significantly.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Ohnishi A, Ohtani H, Sawada Y. Major determinant factors of the extent of interaction between grapefruit juice and calcium channel antagonists. <i>Br J Clin Pharmacol</i>. 2006;62(2):196-199. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16842394\">[PubMed 16842394]</a> </p>\n<p>2. Codipin (benidipine hydrochloride) tablets [Korea KR prescribing information]. Available at: http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=199300958. Accessed October 26, 2017.</p>\n<p>3. Uesawa Y, Mohri K. Relationship between lipophilicities of 1,4-dihydropyridine derivatives and pharmacokinetic interaction strengths with grapefruit juice. <i>Yakugaku Zasshi</i>. 2008;128(1):117-122. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18176062\">[PubMed 18176062]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11892":"<p><b>Title</b> Pitolisant / Probenecid</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Probenecid may decrease the serum concentration of Pitolisant. <b>Severity</b> Minor <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> The pitolisant prescribing information states that in a clinical multiple dose study, the coadministration of pitolisant and probenecid decreased the AUC of pitolisant by about 34%.<sup>1</sup> <br><br>The clinical significance and mechanism of this potential interaction is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Wakix (pitolisant) [EMA summary of product characteristics]. Paris, France: Bioprojet Pharma; November 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11893":"<p><b>Title</b> Anti-inhibitor Coagulant Complex (Human) / Emicizumab-kxwh</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Emicizumab-kxwh may enhance the thrombogenic effect of Anti-inhibitor Coagulant Complex (Human). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Carefully consider the potential risks and benefits of this combination. Patients receiving this combination should be monitored closely for evidence of thrombotic events, including but not limited to thrombotic microangiography (TMA), and promptly stop aPCC and temporarily stop emicizumab-kxwh if there is any evidence of TMA or other thrombotic events.</p> \n<p><b>Discussion</b> According to emicizumab-kxwh labeling, both thromboembolic events and TMA have been reported in some patients receiving both emicizumab-kxwh and activated prothrombin complex concentrate (aPCC) (at cumulative amounts of more than 100 U/kg/24 hrs) for 24 hours or more.<sup>1</sup> Thrombotic events have been reported in 1.1% to 5.6% of patients receiving at least one dose of aPCC, and TMA has been reported in 1.6% to 8.3% of patients receiving at least one dose of aPCC in clinical trials of emicizumab-kxwh, with improvement noted within a week of aPCC discontinuation.<br><br>The specific mechanism for this potential interaction is not clear but likely represents additive pro-coagulant effects.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Hemlibra (emicizumab-kxwh) [prescribing information]. South San Francisco, CA: Genetech, Inc.; November 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11894":"<p><b>Title</b> MetroNIDAZOLE (Systemic) / Cimetidine</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Cimetidine may increase the serum concentration of MetroNIDAZOLE (Systemic). <b>Severity</b> Minor <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> No action required other than routine monitoring of metronidazole therapy in patients who receive cimetidine.</p> \n<p><b>Discussion</b> Three pharmacokinetic studies (N=6 to 7) have demonstrated that cimetidine (600 mg twice daily, 1,000 mg daily, or 1,000 mg single dose) had no effect on the exposure or clearance of metronidazole.<sup>1,2,3</sup> One study did find that the renal clearance of metronidazole was reduced in the presence of cimetidine, but because the renal clearance only accounts for less than 15% of total metronidazole clearance, metronidazole exposure was unchanged.<sup>3</sup><br><br>In contrast, one study of 6 healthy volunteers found that cimetidine (400 mg twice daily for 6 days) decreased the metronidazole (400 mg single IV dose) clearance 29% and increased the metronidazole half-life from 6.2 to 7.9 hours.<sup>4</sup><br><br>At this time, current prescribing information indicates the potential for metronidazole toxicity exists because cimetidine may decrease its metabolism and, therefore, decrease the clearance of metronidazole.<sup>5</sup> Based on the majority of the primary literature suggesting the risk for metronidazole toxicity is significantly less, routine monitoring of metronidazole therapy in the presence of cimetidine may be sufficient.<br><br>The mechanism of this potential interaction may be due to cimetidine-mediated inhibition of CYP3A4, a minor pathway involved in metronidazole metabolism. Because CYP2A6 is mainly responsible for metronidazole metabolism, cimetidine-mediated inhibition of CYP3A4 likely has only a minor effect on metronidazole exposure.<sup>6,7</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Eradiri O, Jamali F, Thomson AB. Interaction of metronidazole with phenobarbital, cimetidine, prednisone, and sulfasalazine in Crohn's Disease. <i>Biopharmaceut Drug Dispos.</i> 1988;9(2):219-227. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2897213\">[PubMed 2897213]</a></p>\n<p>2. Loft S, Dossing M, Sonne J, Dalhof K, Bjerrum K, Poulsen HE. Lack of effect of cimetidine on the pharmacokinetics of metabolism of a single oral dose of metronidazole. <i>Eur J Clin Pharmacol.</i> 1988;35(1):65-68. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3220096\">[PubMed 3220096]</a></p>\n<p>3. Loft S, Sonne J, Poulsen HE, Petersen KT, Jorgensen BG, Dossing M. Inhibition and induction of metronidazole and antipyrine metabolism. <i>Eur J Clin Pharmacol.</i> 1987;32(1):35-41. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3582467\">[PubMed 3582467]</a></p>\n<p>4. Gugler R, Jensen JC. Interaction between cimetidine and metronidazole. <i>N Eng J Med</i> 1983;309(24):1518-1519. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6646177\">[PubMed 6646177]</a></p>\n<p>5. Viaflex Plus Container (metronidazole injection) [prescribing information]. Deefield, IL: Baxter Healthcare Corporation; December 2017.</p>\n<p>6. Pearce RE, Cohen-Wolkowiez M, Sampson MR,Kearns GL. The role of human cytochrome P450 enzymes in the formation of 2-hydroxymetronidazole: CYP2A6 is the high affinity (low Km) catalyst. <i>Drug Metab Dispos.</i> 2013;41(9):1686-1694. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23813797\">[PubMed 23813797]</a></p>\n<p>7. Loft S, Otton SV, Lennard MS, Tucker GT, Poulsen HE . Characterization of metronidazole metabolism by human liver microsomes. <i>Biochem Pharmacol.</i> 1991;41(8):1127-1134. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2009091\">[PubMed 2009091]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11895":"<p><b>Title</b> Lithium / MetroNIDAZOLE (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> MetroNIDAZOLE (Systemic) may enhance the adverse/toxic effect of Lithium. MetroNIDAZOLE (Systemic) may increase the serum concentration of Lithium. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for signs and symptoms of lithium toxicity (eg, lethargy, muscle weakness, impaired cognitive function) and other adverse effects of lithium, such as, decreased renal function, in patients who also receive metronidazole. Serum lithium concentrations, serum creatinine, electrolyte levels and other renal function tests should be monitored as appropriate and doses of lithium adjusted accordingly.</p> \n<p><b>Discussion</b> In 1 out of 2 cases, a 34-year-old patient receiving lithium therapy (1500 mg daily) for 8 years averaged serum lithium concentrations of 1.09 mmol/L. <sup>1</sup> Two days following metronidazole therapy (250 mg 3 times daily for 1 week), these concentrations increased to 1.1 mmol/L and serum creatinine increased from 90 to 140 micromol/L. <sup>1</sup> One month after discontinuing metronidazole, the patient experienced polyuria and nocturia, which subsided with a lower dose of lithium (900 mg daily). Serum creatinine, however, remained elevated (180 micromol/L) up to 5 months post metronidazole.<sup>1</sup> The second case was similar with increased serum lithium concentrations (2 mmol/L from baseline of 0.89 mmol/L) and serum creatinine (140 micromol/L from baseline of 100 micromol/L) following metronidazole (500 mg twice daily for 1 week).<sup>1</sup> Two weeks after discontinuing antibiotic therapy, the patient experienced confusion and muscle weakness while walking. The patient also experienced elevated levels of sodium as high as 162 mmol/L and abnormally diluted urine up to 6 months following metronidazole.<sup>1</sup> Although there were no signs of initial lithium toxicity in either of these cases, symptoms surfaced within weeks after discontinuing metronidazole and evidence of renal damage prolonged for a number of months following metronidazole therapy. <br><br>According to prescribing information, short-term metronidazole therapy has been associated with increased serum concentrations of lithium and, in some cases, lithium toxicity in patients receiving high-dose lithium therapy. Increased monitoring of serum lithium concentrations and renal function are, therefore, recommended if metronidazole therapy is coadministered.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Teicher MH, Altesman RI, Cole JO, Schatzberg AF. Possible nephrotoxic interaction of lithium and metronidazole. <i>JAMA.</i> 1987;257(24):3365-3366. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3586264\">[PubMed 3586264]</a></p>\n<p>2. Viaflex Plus Container (metronidazole injection) [prescribing information]. Deerfield, IL: Baxter Healthcare Corporation; December 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11896":"<p><b>Title</b> Gelatin (Succinylated) / Angiotensin-Converting Enzyme Inhibitors</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Angiotensin-Converting Enzyme Inhibitors may enhance the adverse/toxic effect of Gelatin (Succinylated). Specifically, the risk of a paradoxical hypotensive reaction may be increased. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for a hypotensive reaction if gelatin (succinylated) is given to patients currently taking angiotensin-converting enzyme inhibitors.</p>\n<div>\n <p><b>Angiotensin-Converting Enzyme Inhibitors Interacting Members</b> Alacepril, Benazepril, Captopril, Cilazapril, Enalapril, Enalaprilat, Fosinopril, Imidapril, Lisinopril, Moexipril, Perindopril, Quinapril, Ramipril, Trandolapril, Zofenopril</p>\n</div> \n<p><b>Discussion</b> One report describes 3 patients taking angiotensin-converting enzyme (ACE) inhibitors who experienced profound and refractory hypotension after initiation of gelatin (succinylated) during orthopedic surgery.<sup>1</sup> An anaphylactoid reaction was ruled out in 2 of the 3 cases.<sup>1</sup> <br><br>At least one gelatin (succinylated) product label states that paradoxical hypotensive reactions have been reported to occur in patients receiving gelatin-based plasma volume expanders concurrently with ACE inhibitors.<sup>2</sup> Caution is advised when using gelatin (succinylated) in patients receiving ACE inhibitors, particularly in association with albumin.<sup>2</sup><br><br>The mechanism of this interaction has not been fully investigated, but use of gelatin (succinylated) may lead to activation of bradykinin, an endogenous vasodilator that is present at elevated concentrations during ACE inhibitor use.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Powell CG, Unsworth DJ, McVey FK. Severe hypotension associated with angiotensin-converting enzyme inhibition in anaesthesia. <i>Anaesth Intensive Care</i>. 1998;26(1):107-109. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9513677\">[PubMed 9513677]</a></p>\n<p>2. Gelofusine (succinylated gelatin) [summary of product characteristics]. Bella Vista, New South Wales, Australia: B. Braun Australia Pty Ltd; June 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11897":"<p><b>Title</b> QTc-Prolonging Agents (Highest Risk) / Pefloxacin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Pefloxacin may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for increased QTc interval and arrhythmias (ie, torsades de pointe) if pefloxacin is combined with other drugs known to prolong the QTc interval.</p>\n<div>\n <p><b>QTc-Prolonging Agents (Highest Risk) Interacting Members</b> Ajmaline, Amiodarone, Anagrelide, Arsenic Trioxide, Artemether, Asenapine, Astemizole, Bepridil, Cisapride, Citalopram, Deutetrabenazine, Disopyramide, Dofetilide, Domperidone, Dosulepin, Dronedarone, Eliglustat, FLUoxetine, Flupentixol, Halofantrine, Ibutilide, Iloperidone, Lopinavir, Lumefantrine, MiFEPRIStone, Nilotinib, Paliperidone, Pimavanserin, Pimozide, Pipamperone [INT], Procainamide, QUEtiapine, QuiNIDine, QuiNINE, Radotinib, Ribociclib, Sotalol, Sparfloxacin, Sulpiride, Terfenadine, Tetrabenazine, Thioridazine, Toremifene, Vandetanib, Vemurafenib, Vernakalant, Ziprasidone, Zuclopenthixol</p>\n</div> \n<p><b>Discussion</b> The QTc-prolonging potential of pefloxacin has not been evaluated in a clinical study. However, because pefloxacin is a fluoroquinolone antibiotic, a class of agents associated with QTc prolongation, the pefloxacin product label states that if pefloxacin is combined with other QT-prolonging medications, patients should be monitored closely.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Pefloxacin tablet [KR prescribing information]. Available at: http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=199101448. Accessed October 26, 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11898":"<p><b>Title</b> Theophylline Derivatives / Pefloxacin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Pefloxacin may increase the serum concentration of Theophylline Derivatives. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for increased theophylline derivative concentrations and effects if combined with pefloxacin. Theophylline derivative dose reductions may be required.</p>\n<div>\n <p><b>Theophylline Derivatives Interacting Members</b> Acebrophylline, Aminophylline, Theophylline<br><b>Exception</b> Dyphylline</p>\n</div> \n<p><b>Discussion</b> In a pharmacokinetic study of 8 patients taking theophylline, the addition of pefloxacin (400 mg twice daily) increased the theophylline AUC and maximum serum concentration (Cmax) 53% and 20%, respectively.<sup>1,2</sup> Another pharmacokinetic study in 5 healthy volunteers found that pefloxacin (200 mg twice daily) increased the AUC and Cmax of theophylline (200 mg twice daily) 22% after 5 days of concomitant therapy.<sup>3</sup><br><br>The pefloxacin product labeling states that theophylline concentrations may increase if combined with pefloxacin.<sup>4</sup> If these agents are combined, patients should be monitored for theophylline toxicity and theophylline dose reductions may be necessary.<sup>4</sup><br><br>The mechanism of this interaction is likely due to pefloxacin-mediated inhibition of CYP1A2, an enzyme responsible for theophylline metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Wijnands WJ, Vree TB, van Herwaarden CL. The influence of quinolone derivatives on theophylline clearance. <i>Br J Clin Pharmacol</i>. 1986;22(6):677-683. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3567014\">[PubMed 3567014]</a></p>\n<p>2. Wijnands WJ, Vree TB, Baars AM, van Herwaarden CL. The influence of the 4-quinolones ciprofloxacin, pefloxacin, and ofloxacin on the elimination of theophylline. <i>Pharm Weekbl Sci</i>. 1987;9(suppl):S72-S75. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3481439\">[PubMed 3481439]</a></p>\n<p>3. Niki Y, Soejima R, Kawane H, Sumi M, Umeki S. New synthetic quinolone antibacterial agents and serum concentration of theophylline. <i>Chest</i>. 1987;92(4):663-669. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3477409\">[PubMed 3477409]</a></p>\n<p>4. Pefloxacin tablet [KR prescribing information]. Available at: http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=199101448. Accessed October 26, 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11899":"<p><b>Title</b> Thyroid Products / Somatropin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Somatropin may diminish the therapeutic effect of Thyroid Products. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for reduced thyroid product effectiveness (eg, decreased T4, increased TSH) if combined with somatropin.</p>\n<div>\n <p><b>Thyroid Products Interacting Members</b> Levothyroxine, Liotrix, Thyroid, Desiccated<br><b>Exception</b> Liothyronine</p>\n</div> \n<p><b>Discussion</b> In a retrospective study of 108 patients with central hypothyroidism, 27 patients who were concomitantly treated with growth hormone (ie, somatropin) required higher doses of levothyroxine compared with 81 patients who received levothyroxine without growth hormone (1.8 mcg/kg/day vs 1.6 mcg/kg/day).<sup>1</sup><br><br>The somatropin prescribing information states that growth hormone can affect the metabolism of thyroid hormones by increasing the extrathyroidal conversion of T4 to T3.<sup>2</sup> This can result in reduced T4 concentrations and clinical hypothyroidism.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Alexopoulou O, Beguin C, De Nayer P, Maiter D. Clinical and hormonal characteristics of central hypothyroidism at diagnosis and during follow-up in adult patients. <i>Eur J Endocrinol</i>. 2004;150(1):1-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14713273\">[PubMed 14713273]</a></p>\n<p>2. Zorbtive (somatropin) [prescribing information]. Rockland, MA: EMD Serono Inc; May 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>"}